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ABSTRACT 
 
Background: Type 2 diabetes mellitus (T2DM) is defined by an increase in serum 
glucose, however, this leads to the belief that only the serum glucose levels need be 
monitored and treated. Hence many other risk factors such as obesity, lipids and 
blood pressure which increase the risk of coronary heart disease, myocardial 
infarction, stroke and peripheral vascular disease are neglected. Consequently, 
T2DM patients that are at greater risk of developing cardiovascular disease (CVD), 
are often not receiving optimal comprehensive care.  
 
Aims: To identify the treatment gaps of cardiovascular risk factors in patients with 
T2DM using both national and international current treatment guidelines. 
 
Methods: Using a public sector database, data was obtained on the treatment of 666 
T2DM patients. Records of patients were selected on the basis of established T2DM 
diagnoses, receiving oral hypoglycaemic and/or insulin therapy. The following patient 
data was recorded: demographics (age, gender, ethnicity), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), glycated haemoglobin (HbA1c), total 
cholesterol (TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-
C) , family history, cardiovascular history and all chronic medications.  The following 
parameters were applied to the cohort: SBP <130 mmHg, DBP <80 mmHg. In the 
event of proteinuria: SBP ≤120 mmHg, DBP ≤70 mmHg. HbA1c <7.0%, TC <4.5 
mmol/L, LDL-C <2.5 mmol/L, HDL-C >1.0 mmol/L (males), HDL-C >1.2 mmol/L 
(females) and TG <1.7 mmol/L. In patients with established CVD, LDL-C target: ≤1.8 
mmol/L. 
 
Results: The study cohort consisted of 666 T2DM-patients. 55% females. Mean age 
was 63 years (SD: 11.8), mean HbA1c was 8.7% (SD: 2.4). The mean SBP and DBP 
readings for the cohort were 133.66 (SD: 19.9) and 78.07 mmHg (SD: 11.6), 
respectively. Mean LDL-cholesterol was 2.6 mmol/L (SD: 0.9). 26.2% reached HbA1c 
of ≤7%, 45.8% reached ≤130/80 mm Hg blood pressure targets, 53.8% reached 
LDL-C of ≤2.5mmol/L and all 3 were reached by 7.5% of the cohort. TC ≤4.5 mmol/L 
was reached by 53.8%, 60.2% reached TG ≤1.7mmol/L, 58.6% males and 52.8% 
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females reached HDL-C targets of ≥1.0 mmol/L and ≥1.2 mmol/L, respectively. There 
were 17.9% of patients with CVD reaching targets of LDL-C ≤1.8 mmol/L whilst 
16.4% of patients with nephropathy reaching targets of ≤120/70 mm Hg. Almost half 
(48.2%) were not receiving lipid-lowering therapy, yet would be deemed eligible for 
therapy. Blood pressure targets may have been better reached with appropriate 
dosage reductions in addition to the introduction of further antihypertensive 
combination therapy. CVD was present in 15.5%. 
 
Conclusions: T2DM patients are at high-risk for CVD. Many trials have 
demonstrated the benefits of targeting CVD risk factors (HbA1c, blood pressure, 
serum lipids) in T2DM. Less than 10% of CVD risk factor targets were reached by the 
study cohort despite treatment guideline recommendations. The data from the study 
suggests poor control of modifiable cardiovascular risk factors and significant under 
treatment of T2DM in clinical practice. Whether improvement lies in the form of 
therapeutic titration adjustment or an increase in patient education, there needs to be 
a more aggressive multi-factorial therapeutic approach to treating this high risk group 
of patients in order to reduce overall morbidity, mortality and improve patient 
outcomes. 
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INTRODUCTION 
 
Diabetes mellitus (DM) is a serious, multifaceted condition, which is also one of the 
most common life-threatening diseases around the globe. Diabetes Mellitus 
outweighs HIV/AIDS prevalence by 5 to 1; in 2000, there were approximately 36.1 
million people living with HIV/AIDS, in the same year, approximately 171 million 
Diabetics.1 2 By 2025, an estimated 380 million people will be living with diabetes 
worldwide.3  
 
Diabetes Mellitus Type 1 
 
Type 1 diabetes mellitus (T1DM), previously known as “Insulin Dependent Diabetes 
Mellitus,” is thought to be caused by viral agent(s) or an interaction between genes 
and the immune system. In the autoimmune form, antibodies destroy the  cells of 
the pancreas, which leads to an absolute deficiency in insulin production. The 
autoimmune disorder form is the most common kind of type 1 diabetes mellitus and 
insulin administration is the therapeutic approach for all type 1 diabetics.4 
 
Diabetes Mellitus Type 2 
 
Type 2 diabetes mellitus (T2DM), was once known as “Non-Insulin Dependent 
Diabetes Mellitus” and is a metabolic disorder that is characterised by a diminished 
sensitivity of the target tissues to insulin. This results in “insulin resistance” which 
further leads to chronic hyperglycaemia. The progressive nature of this disease may 
also lead to the decreased  cell function of the pancreas,5 consequently leading to a 
state of relative insulin deficiency. Unlike type 1, most type 2 diabetics are 
overweight or obese at the time of diagnosis and may have the “metabolic 
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syndrome.” In order to combat this type of diabetes mellitus, lifestyle modifications 
such as decreased caloric intake, increased physical activity, weight loss and stress 
reduction are advocated. Despite these lifestyle modifications, the bulk of patients 
are still incapable of maintaining normoglycaemia without drug therapy. Oral 
hypoglycaemic agents are used to maintain glycemic control in type 2 diabetic 
patients. The major classes include: 
 Insulin Secretagogues e.g. Sulphonylureas – stimulate insulin release from 
the pancreas. 
 Meglitinides - structurally different from Insulin Secretagogues, yet also 
stimulate insulin release from the pancreas. 
 Biguanides - enhance peripheral tissue sensitivity to insulin thereby increasing 
glycolysis and decreasing hepatic and renal gluconeogenesis. 
 -Glucosidase Inhibitors - divert and prolong the postprandial digestion and 
absorption of starch and disaccharides. 
 Insulin Sensitizers e.g. Thiazolidinediones - correct insulin resistance by 
regulating genes involved in glucose, lipid metabolism and adipocyte 
differentiation.   
When oral hypoglycaemic agents fail, insulin therapy is added in order to meet 
glycaemic target levels. 
 
Microvascular Aspect of Type 2 Diabetes Mellitus 
 
The high glucose load puts a huge strain on a number of different pathways. In type 
2 diabetes, it has been clearly recognized that raised glucose levels ultimately result 
in microvascular complications. 6 Microvascular complications include retinopathy, 
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which results in visual impairment or blindness, nephropathy, which leads to renal 
failure, and neuropathy, which can cause paresthesia.7 8  
 
The landmark UKPDS study enrolled over 5000 type 2 diabetic patients and showed 
a 25% decline in microvascular complications when intensive glycemic control was 
achieved. Hence, glycemic control is an essential factor in decreasing the risk of 
microvascular complications in diabetic patients.9 Poor glycemic control in type 2 
diabetics is an independent predictor of vascular diseases.10 11 In the same study, in 
the group with tight glycaemic control, there was a 14% and 21% decline in 
myocardial infarcts and diabetes-related mortalities respectively. The Honolulu Heart 
Program determined that cardiovascular mortality in type 2 diabetics was 
proportional to long term serum glucose concentrations as measured by HbA1c.
12  
This suggests that tight glycemic control can reduce microvascular complications and 
at the same time, make an impact on macrovascular complications.  
 
Macrovascular Aspect of Type 2 Diabetes Mellitus 
 
The focus in the diabetes mellitus type 2 condition is serum glucose. This however, 
leads to the belief that only the serum glucose levels need be monitored and treated. 
Hence many other risk factors such as lipids, cholesterol and blood pressure which 
increase the risk of coronary heart disease, myocardial infarction, stroke and 
peripheral vascular disease are ignored.  
 
Cardiovascular disease (CVD) is widespread in patients with type 2 diabetes 
mellitus.13 Type 2 diabetics have a 2 to 4 fold increased risk of cardiovascular 
episodes compared with non-diabetics.14 15   Haffner et al. concluded from 
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epidemiological data that type 2 diabetic subjects are as much at risk of suffering a 
myocardial infarction as non-diabetic subjects who previously suffered a myocardial 
infarction.14 At least 80% of people with type 2 diabetes mellitus die from some form 
of cardiovascular disease.16 17 This makes diabetes mellitus an independent risk 
factor for cardiovascular diseases.  
 
The role of dyslipidaemia in coronary heart disease is well-described.18 The 
INTERHEART study conducted by Yusuf et al., in 2004 showed that, amongst other 
risk factors, dyslipidaemia was associated with myocardial infarctions.19 
Hyperlipidaemia results in cardiovascular complications such as premature 
progression of atherosclerosis, coronary artery disease, peripheral vascular 
diseases, thromboembolic stroke and myocardial infarctions.20 21 
 
Dyslipidaemia is common in type 2 diabetic patients due to genetic predispositions 
and/or obesity.22 Dyslipidaemia in type 2 diabetes is distinguished by small, dense 
atherogenic LDL cholesterol, high plasma triglycerides and reduced HDL cholesterol 
levels. This is frequently associated with coronary heart disease.23 LDL cholesterol 
levels in type 2 diabetics are often similar to the levels in non-type 2 diabetics. 
Nonetheless, type 2 diabetics are still at higher risk for the development of 
atherosclerosis because of the absolute number of small dense LDL particles.24 25 26 
An additional study demonstrated that coronary artery disease (CAD) was the 
foremost source of death among diabetic patients as a result of dyslipidaemia.27 By 
treating dyslipidaemia in patients with Type 2 diabetes, cardiovascular diseases are 
considerably decreased in incidence.28  
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Type 2 diabetics are particularly at risk of developing coronary heart diseases. This 
highlights how crucial primary prevention is within this population. The normal to 
slightly raised LDL cholesterol levels often makes lipid-lowering therapy unjustified 
for cardiovascular disease in type 2 diabetes. However, clinical trials have been 
conducted and support the contention that lipid-lowering treatment in diabetic 
patients reduces cardiovascular disease, regardless of LDL cholesterol levels at 
entry.29 In the Collaborative Atorvastatin Diabetes Study (CARDS), type 2 diabetics 
with no prior history of cardiovascular disease were given atorvastatin (HMG-CoA 
reductase inhibitor) 10mg daily and showed a massive 37% reduction in major 
cardiovascular events. 29 Furthermore, there was a decline by 36% in acute coronary 
heart disease, 31% decline in revascularisations, 48% decline in strokes and overall 
mortality was reduced by a substantial 27%. This proves the benefit of lipid-lowering 
therapy in the primary prevention of cardiovascular disease in type 2 diabetics, 
despite the “normal” LDL cholesterol levels.  
 
Other studies have also shown similar trends, including the Cholesterol and 
Recurrent Events (CARE),30 Long-term Intervention with Pravastatin in Ischemic 
Disease (LIPID),31 the Lescol Intervention Prevention Study (LIPS),32 the Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA)33 and the 
Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-
Insulin-Dependent Diabetes Mellitus (ASPEN).34  These studies had diabetic 
subgroups large enough to prove the efficacy of lipid-lowering therapy in secondary 
prevention of heart diseases.  
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The Heart Protection Study (HPS) enrolled over 20 000 patients, which consisted of 
5963 diabetic patients, of which 2912 patients had no prior cardiovascular disease.28 
Lipid lowering therapy led to the entire diabetic group showing a 27% reduced risk of 
major coronary events (20% reduction in coronary mortality and 37% reduction in 
first non-fatal myocardial infarction), 17% reduction in revascularisations and a highly 
noteworthy 22% reduction in major vascular events. In the 2912 diabetic subgroup 
without documented coronary or other occlusive arterial diseases, a striking 33% 
proportional reduction in first major vascular events occurred. The HPS provided an 
indication of how cholesterol-lowering therapy in type 2 diabetics reduces the risk of 
heart attacks, strokes, and revascularisations, especially in primary prevention. The 
benefit was also seen in patients with LDL below 3.0 mmol/L in particular- by 
showing reductions in vascular events by as much as 27%. This further 
demonstrated how lipid-lowering therapy should be used consistently for all type 2 
diabetics, irrespective of their initial cholesterol levels.  
 
The Scandinavian Simvastatin Survival Study (4S), one of the first studies to 
establish the effectiveness of HMG-CoA reductase inhibitors in secondary 
prevention, demonstrated that diabetic patients being treated with simvastatin (an 
HMG-CoA reductase inhibitor) lowered the relative risk of death by 43%, as well as 
lowered their relative risk of any atherosclerotic event by 37%.35 This confirms the 
potential of lipid-lowering therapy with regards to decreasing the risk of major 
coronary events in secondary prevention, in spite of baseline risk factors such as 
diabetes mellitus. It is clear that there is a robust relationship between type 2 
diabetes mellitus and cardiovascular disease.  
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The Treatment Of Cardiovascular Risk Factors In Type 2 Diabetes 
Mellitus 
 
Cardiovascular disease is common in South Africa.36 In a study conducted at 9 South 
African township communities of 1691 subjects (an estimated 0.2% of the total 
population), 78% of subjects screened positive for at least one major cardiovascular 
risk factor for CVD.37 Not only is CVD prevalent in South Africa but also often left 
undiagnosed. A South African health survey revealed that Nearly 6 million South 
Africans aged 15 years and older suffered from hypertension, of which only 26% of 
men and 51% of women knew that they had had hypertension.38 CVD left untreated 
results in many complications. In another South African study (at a hypertension 
clinic), congestive heart failure was the most common form of mortality.39  
 
The link between CVD and T2DM is clear.14 T2DM is an established and highly 
prevalent risk factor for cardiac morbidity and mortality. Long considered a disease of 
minor significance to world health, T2DM is now taking its place as one of the main 
threats to human health in the 21st century.40 Changes in human environment, 
behaviour and lifestyle have accompanied globalization and these have resulted in 
escalating rates of both obesity and diabetes. Hence the adoption of the term 
“diabesity.” 41  
 
The treatment in patients with T2DM has traditionally centred around correcting 
blood glucose levels and this claims most of the resources. Yet, as many as 80% of 
people with T2DM will die from some form of CVD, highlighting the need for more 
aggressive intervention.16 This makes T2DM an independent risk factor for CVD. 
Targeting blood glucose levels may reduce microvascular complications, but this will 
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only slightly improve patient outcomes if other cardiovascular risk factors, namely 
blood pressure and serum lipids are left untreated. 28 42    
 
Blood pressure and serum lipid targets are far more stringent in this group than in 
non-diabetics, thus requiring more intensive therapy.43 The accelerated 
atherosclerosis which predisposes T2DM patients to increased incidence of 
premature cardiovascular events has been demonstrated in epidemiological studies 
and major clinical trials.28 29 44 45  Risk factors in T2DM such as dyslipidaemia, 
hypertension and obesity which are commonly associated with T2DM have increased 
the incidence and progression of cardiovascular related events. Not surprisingly, 
T2DM has been classified as a “CVD-equivalent” necessitating secondary prevention 
treatment.14  
 
In T2DM, premature morbidity and mortality associated with the disease warranted a 
way in which complications could be overted.40 Over the last decade, major studies 
such as the UKPDS and DCCT established the need for stricter control of blood 
glucose in order to reduce or prevent the risk of both the microvascular and (to a 
lesser degree) macrovascular complications.6 9 However, recent evidence has 
shown that over treating glucose levels may in fact negatively impact patient 
outcomes through episodes of hypoglycaemia.46 Similarly, a recent review by the 
Cochrane Collaboration concluded with: “Treating patients to lower than standard BP 
targets, ≤140-160/90-100 mmHg, does not reduce mortality or morbidity.” 47 
Neglecting or over treating the cardiovascular risk factors in T2DM will lead to 
complications, perhaps a more careful approach is the way forward.       
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Global Treatment Of Cardiovascular Risk Factors In Type 2 Diabetics  
 
With T2DM patients being at a markedly increased risk for CVD, the latest evidence 
has resulted in T2DM treatment guidelines being more “cardiovascular risk factor” 
focused with regards to patient treatment and management.48 Treatment guidelines 
in general are designed to influence the practitioner‟s method of treating patient risk 
factors in order to help better patient outcomes. Optimal management of T2DM risk 
factors offered in various treatment guidelines advocate stricter goals or treatment 
targets for T2DM patients in order to reduce patient morbidity and mortality. 
However, many T2DM patients, even those in resource rich countries still lack control 
of the key risk factors leading to complications. The following studies have been 
selected and carefully reviewed for the purposes of comparison. Although the studies 
may have varied by location, demographic population and national targets (specific 
to the country), all studies chosen have a core purpose and that is of investigating 
the treatment of cardiovascular risk factors in T2DM patients in practice. 
 
Italy. In an Italian 2004 observational study where 2465 patients were recruited from 
10 different hospitals across the country, 5% of the total targets were achieved by 
patients for LDL-C, BP, HbA1c and smoking habits with mean lipid and BP readings 
significantly higher than recommended cardiovascular guidelines.49 Gender 
difference studies revealed that women were worse off than men with regards to their 
weight, HbA1c, LDL-C, SBP, but not smoking habits. Patients with a longer duration 
of diabetes tended to have a higher HbA1c and SBP, but were less obese, had lower 
DBP and smoked less than patients with shorter duration of diabetes. Evidently, 
despite clear recommendations from the Italian Diabetes Society,50 the majority of 
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T2DM patients in Italy aren‟t being treated appropriately for their cardiovascular risk 
factors. 
   
Norway. This study, recommended by the Regional Ethics Committee and Research 
Board of the Norwegian College of General Practitioners (NSAM) comprised of 975 
T2DM patients which were recruited from 5 major regions across Norway.51 Some 
13% and 6% of the total cohort achieved goals for glucose, BP and cholesterol 
control using national and IDF guidelines, respectively. No major gender differences 
were found. 79% had metabolic syndrome according to WHO definition. 65% and 
35% of the total cohort achieved NSAM and IDF glucose targets, respectively. BP 
targets (≤140/85 mmHg) were reached by 52%, whilst 32% achieved LDL-C targets 
(<3 mmol/L).  73% of patients with CVD, whilst 27% of patients without CVD but with 
other risk factors such as hypertension, microalbuminuria and smoking received lipid-
lowering therapy. Conclusions from the study reflect on compliance with national 
targets being more often achieved with glycaemic control than with BP and 
cholesterol.  
 
Spain. A 2003 cross-sectional study was conducted in order to assess the “degree of 
control of modifiable cardiovascular risk factors” in 501 T2DM patients.52 The cohort 
comprised of patients recruited from a specialized secondary referral centre that 
provides healthcare to 31 districts in Madrid, Spain. With no significant differences 
between genders, 41% of the total population achieved both HbA1c (< 7 %) and LDL-
C targets (< 2.6mmol/L). More patients with CAD received statins than those without 
CAD, which explains why more of these patients were at goal for LDL-C (53% vs. 
31%, p = 0.0006). 27% and 72% of patients were at goal for SBP (<130 mmHg) and 
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DBP (<80 mmHg), respectively. Amongst glucose-related levels (HbA1c, fasting 
plasma glucose, postprandial capillary glucose), lipid levels and BP readings, other 
parameters included in the study consisted of body mass index (BMI), waist 
circumference (WC), smoking status and medications. None of the 501 patients 
achieved target for all the risk factors tested. A correlation was seen in patients with 
established CAD; these patients tended to receive more insulin than oral 
hypoglycaemics as well as had more risk factors present, which may be indicative of 
the progressive nature of DM and its impact on heart disease. Overall, in view of the 
poor control achieved and none of the patients being at targets for risk factors tested, 
the study investigators called for a more aggressive approach to combating 
“modifiable cardiovascular risk factors” in T2DM patients.  
 
Czech Republic. This study comprised of 3206 randomly selected patients from 89 
outpatient clinics across the Czech Republic.53 Conducted in 2002, retrospective 
patient data such as lipids, BP and HbA1c were captured from records. Using ADA-
based national T2DM guidelines,48 results revealed the following: 42% of patients 
achieved HbA1c <7.0%, 31% achieved SBP <130 mmHg, 63% achieved DBP <80 
mm Hg, 27% achieved TC <5.0 mmol/L, 55% achieved HDL-C above 1.1 mmol/L 
and finally 56% achieved triglycerides below 2.0 mmol/L. Combined, only 1% of all 
study T2DM patients achieved goals for all three parameters. The investigators also 
investigated the use of pharmacological treatment and found that patients were 
largely under-treated. It was clear that T2DM treatment guidelines simply were not 
being implemented properly. It was also mentioned that patients need to be 
evaluated more intensely for their risk factors, “to minimize the number of 
unrecognized cases.” Non-pharmacological advice such as lifestyle modifications 
12 | P a g e  
 
and better self-monitoring was also re-enforced. It was concluded that improved 
outcomes are expected through increased guideline adherence using readily 
available non-drug and drug technologies in order to target under-treatment of 
T2DM. 
 
South Africa. Two local South African studies were conducted to determine 
cardiovascular risk factor treatment in T2DM patients in 1996 and 2006, 
respectively.54 55 In the former study, eighty-two patients were recruited and tested 
for obesity, smoking status, lipid, HbA1c and blood pressure levels. Results indicated 
that 82% of total patients were obese, 66% had hypertriglyceridaemia, 46% had 
hypercholesterolaemia and 20% had uncontrolled hypertension. Other 
cardiovascular risk factors such as smoking were present in 27%. Outcomes from 
the study indicated that patients were not receiving adequate treatment for their 
cardiovascular risk factors. Similar findings were present in the 2006 study. In spite 
of the wealth of clinical evidence available and latest guideline recommendations, it 
appears that DM treatment in practice has largely remained confined to glycaemic 
control. 
 
The latest guidelines issued by the “Society for Endocrinology, Metabolism, and 
Diabetes of South Africa (SEMDSA),56 American Diabetes Association (ADA),48 
International Diabetes Federation (IDF) 57 and European Society of Cardiology / 
European Association for the Study of Diabetes (ESC/EASD) 58 suggest aggressive 
targeting of HbA1c but also blood pressure and dyslipidaemia. But how well do 
treatment guidelines translate into clinical practice and are goals being met? 
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In developing countries with so much competition for scarce resources such as 
antiretrovirals for HIV/AIDS, we wished to document how well T2DM patients were 
being treated in a South African, public sector setting.  
 
The outcome of the two previous South African studies conducted at the 
Johannesburg Academic Hospital revealed that the management of cardiovascular 
risk factors in T2DM patients remains suboptimal.54 55 Results from both these 
studies showed that there is still a significant gap in the management of 
cardiovascular risk factors in T2DM. Following these last two studies, the current 
study was designed to further address the ongoing problem with the management 
cardiovascular risk factors in T2DM. Both previously conducted studies consisted of 
smaller sized cohorts and there has since been emergence of newer evidence 
regarding the management of cardiovascular risk factors in T2DM. The idea behind 
the current study was to augment our understanding of the problems T2DM patients 
face in the management of their cardiovascular risk factors and to see where the 
shortfalls lie. To the knowledge of the author of the current study, no audit of this 
magnitude regarding the treatment of cardiovascular risk factors in T2DM has ever 
been conducted at the Charlotte Maxeke Johannesburg General Hospital. 
 
The cohort of this study comprised of patients initially referred from their primary local 
clinics to a tertiary public sector clinic. This reflects the quality of care the State can 
provide, especially to those in the lower socio-economic class who cannot afford 
private health care. Given that these patients have been referred to the 
Johannesburg Hospital from smaller clinics, these patients which comprise the study 
cohort tend to be more burdened with disease or have a more “advanced form” of 
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diabetes requiring further attention and management.  Targeting of cardiovascular 
risk factors such as blood glucose, blood pressure and serum lipids will most likely 
determine patient outcomes. For these reasons, the current study will enable us to 
determine the extent to which guidelines are being implemented with regards to 
cardiovascular risk factor management in more “complicated” South African T2DM 
patients.  
  
15 | P a g e  
 
Study Objectives 
1. The objectives of this study are to: 
1.1 Determine the current treatment strategies of cardiovascular risk factors 
(HbA1c, blood pressure, serum lipids) in type 2 diabetic patients by 
practitioners at a Johannesburg State Hospital. 
1.2 Determine whether current diabetes treatment guidelines are being 
adhered to by practitioners. 
1.3 Determine the frequency and type of glucose-lowering, anti-hypertensive 
and lipid-lowering treatment in type 2 diabetic patients.  
1.4 Determine the extent to which lipid, glucose and blood pressure targets 
have been achieved in type 2 diabetic patients according to the latest 
national and international diabetes treatment guidelines. 
1.5 Determine the prevalence of cardiovascular disease in type 2 diabetic 
patients and the extent to which lipid levels are controlled in this high-risk 
group.  
1.6 Determine the prevalence of diabetic nephropathy in type 2 diabetic 
patients and the extent to which blood pressure levels are controlled in 
this high-risk group.  
1.7 Compare the attainment of cardiovascular risk factor targets (HbA1c, blood 
pressure, serum lipids) with those of similar studies. 
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STUDY METHODOLOGY 
 
 
Study Design 
 
This was a cross-sectional study conducted at the Charlotte Maxeke Johannesburg 
General Hospital between June 2008 and March 2009. The Johannesburg General 
Hospital is an academic tertiary hospital that provides healthcare services to patients 
across the Gauteng province. Patients that were enrolled in this clinic are generally 
not covered by the private health care industry and are generally from lower socio-
economic strata that cannot afford private healthcare. In addition patients are only 
treated once their treating physician at the local clinics have referred them. Complete 
diabetes management is carried out at the hospital‟s diabetic clinic and patients 
attend the clinic for the purposes of initial and follow-up visits. 
Patients 
 
Patients that met the inclusion criteria of being > 18 years of age and having a 
positive diagnosis for Type 2 Diabetes Mellitus were enrolled into the study. For the 
purposes of this study, patients were assumed to have a positive diagnosis for Type 
2 Diabetes Mellitus as indicated in their medical history (in their hospital files). For 
the current study, the definition of Type 2 Diabetes Mellitus is defined as in any of the 
recognized guidelines as seen under appendices VIII, IX, X and XI. The guidelines 
were assumed to have been followed by the diagnosing registered nurse or 
practitioner at the referral clinic or at the Charlotte Maxeke Johannesburg General 
Hospital at the time of patient diagnosis. To establish an appropriate diagnosis for 
Type 2 Diabetes Mellitus, patients are required to be diagnosed according to 
recognized guidelines such as those under appendices VIII, IX, X and XI. Patients 
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comprising the cohort of the current study were assumed to have been diagnosed 
using recognized guidelines such as those under appendices VIII, IX, X and XI.   
Patients comprising the cohort were selected on the basis of previous T2DM 
diagnosis, eliminating the chance of patient-selection bias in the study. From 782 
patients, the following patients were excluded from the study: 109 Type 1 Diabetic 
patients (study exclusion criteria), 1 gestational Diabetes patient (study exclusion 
criteria) and 1 steroid-induced Diabetes patient (study exclusion criteria). As one of 
the primary measurements was serum lipid readings, it was decided to exclude the 5 
patients with triglyceride levels > 5 mmol/L as this may have been a source of error 
for the calculation of LDL-C or could possibly be non-compliance with overnight 
fasting leading to anomalous lipid readings and in particular, low LDL-cholesterol 
readings. Thus, data from a total of 666 patients which attended the hospital‟s 
diabetic clinic between July 2008 and July 2009 was used for this study.  
All patients seen at the diabetes clinic of the Charlotte Maxeke Johannesburg 
General Hospital are provided with a file where all information regarding hospital 
visits, treatment and medical history is documented. Patient laboratory reports are 
also kept within these files. The files are physically kept at the clinic and are 
maintained by hospital administration clerks. The files are organized into the filing 
cabinets by a unique hospital number given to patients at the hospital, as well as the 
first letter of the patient‟s surname. 
For the purposes of this study, patients were recruited based on the hospital‟s filing 
system which used patient‟s hospital numbers as well as the first letter of their 
surname. Patient files were selected in an alphabetical order, starting from the letter 
A (followed by the assigned hospital number). This method of selecting participants 
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ensured a non-bias selection of participants and to the knowledge of the investigator, 
did not allow for any patients to be favoured over others. 
Using patient records, the following data was captured into case report forms (CRF): 
demographics (age, gender, ethnicity), systolic blood pressure (SBP), diastolic blood 
pressure (DBP), glycated haemoglobin (HbA1c), total cholesterol (TC), triglycerides 
(TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) , family history, 
cardiovascular history and all chronic medications (Figure 50). Only the most recent 
records and laboratory reports of the patient were utilised for the purposes of this 
study.  
Clinical Parameters 
 
Where blood samples were required for laboratory tests, registered nurses were in 
charge of drawing of study patient‟s bloods using standardised techniques at the 
diabetes clinic. Patients were informed of the mandatory fasting requirements of tests 
before having their blood drawn for specific tests (fasting lipids) in prior 
appointments/visits.  
As Charlotte Maxeke Johannesburg Academic Hospital is a state hospital, the 
National Health Laboratory Services (NHLS) was responsible for all the laboratory 
measurements of study patients. Once the results were available, the NHLS issued 
laboratory results delivered by hospital staff to the diabetes clinic and filed under 
respective patient files by clinic administration staff. 
HbA1c was measured using the Tina-Quant Haemoglobin A1c II immunological 
assay, fasting LDL-C was determined indirectly using the Friedewald formula,59 
fasting HDL-C was measured by direct enzymatic methods (HDL-C plus 3rd 
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generation), fasting TC was also measured by direct enzymatic methods (CHOD-
PAP) and TG  were measured by enzymatic colorimetric methods (GPO-PAP). All 
measurements were done using the Modular Analyser P800 System (Roche 
Diagnostics-Hitachi, Mannheim, Germany).  
Blood pressure readings used for the study were measured by registered nurses or 
treating doctors at the clinic. It is advised for treating nurses or practitioners whilst 
performing a blood pressure examination to ensure standardised brachial cuff 
techniques in accordance with the latest South African Hypertension Guidelines 60 
and The Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC VII).61 However, in the 
current study, blood pressure reading data (SBP and DBP) for each patient was 
extracted from patient hospital files meaning that these blood pressure readings were 
measured prior to the study. The initial blood pressure measurement, number of 
blood pressure measurements taken for each patient and whether the mean of two 
or more measurements were used to work out a final measurement was not available 
to the study investigator. The study investigator is not able to confirm proper blood 
pressure technique employed at the time of blood pressure examination. The single 
latest blood pressure measurement, if available, for each patient, from the patient‟s 
respective file was extracted for the purposes of this study. 
As previously mentioned, due to the referral nature of the Charlotte Maxeke 
Johannesburg General Hospital, many patients already presented with previously 
diagnosed complications. Defining patients, for the purposes of this study as having 
diabetic nephropathy using laboratory data, i.e. micro-albumin-to-creatinine ratios, 
serum creatinine concentrations or glomerular filtration rate (GFR) often proved 
inconsistent due to many patients not having these laboratory reports available in 
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their records. It was also found that some patients were concurrently being managed 
at the hospital‟s renal clinic, separate to the diabetic clinic. For the purposes of this 
study, patients deemed as having nephropathy were those patients who had one or 
more of the following in their records: chronic kidney disease (CKD), chronic renal 
disease (CRD), chronic renal failure (CRF), nephropathy and diabetic nephropathy. 
Where patient clinical data (e.g. Blood Pressure readings) was missing from records, 
no random values were registered into the database for those patients. For the 
purposes of calculations, patients with missing clinical data values were excluded 
from certain calculations (Figure 52). Table 1 shows the total number of patient clinical 
parameters available for use in the study for the entire cohort.   
Parameter 
Readings 
(n) 
 
(%) 
Serum Glucose   
HbA1c 623 93.54 
   
Blood Pressure 540 81.08 
Systolic (No Nephropathy) 485 72.82 
Diastolic (No Nephropathy) 485 72.82 
Systolic (Nephropathy) 55 8.26 
Diastolic (Nephropathy) 55 8.26 
   
Plasma Lipids   
Total Cholesterol 595 89.34 
LDL-Cholesterol (No CAD/Stroke) 481 72.67 
LDL-Cholesterol (CAD/Stroke) 94 14.26 
HDL-Cholesterol 580 87.09 
Triglycerides 578 86.79 
 
Table 1 Total clinical data obtained from patient records; Glycated Haemoglobin (HbA1c), 
Coronary Artery Disease (CAD) 
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In statistical calculations, where appropriate, only the necessary variables required 
were used for calculations. 
Most patient files had incomplete details of weight, height, diet details and smoking 
status. These parameters, especially the first two, would have been used to work out 
Body Mass Index (BMI). Since this data was unavailable, no calculations were 
possible. On the same note, due to missing waist measurements, patient 
classification of Metabolic Syndrome (MS) 62 was also omitted from the study.  
 
Once data was captured into case reports, the SEMDSA 2009, American Diabetes 
Association 2008, IDF 2005 and European Society of Cardiology / European 
Association for the Study of Diabetes (ESC/EASD)58 2007 treatment guidelines were 
applied to the cohort. As treating practitioners within South Africa use local guidelines 
(SEMDSA) to treat patients, the national guidelines were primarily used for NAG (Not 
At Goal) and AG (At Goal) studies). At the time of collection (July 2008-July 2009) 
the practitioners may have used the previous SEMDSA 2003 guidelines to manage 
their patients. 
 
For this study, hypercholesterolaemia was defined as total cholesterol >4.5mmol/L 
and hypertriglyceridaemia as triglycerides >1.7 mmol/L. Patients receiving lipid-
lowering therapy were not classified as having hyperlipidaemia as therapy could 
have been instituted for either primary or secondary prevention purposes. Patients 
were considered hypertensive if they were being treated with hypertensive 
medication, as many patients on therapy had controlled blood pressure levels. In 
instances where patients were not being treated with an oral hypoglycaemic or 
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insulin therapy or a combination of both, lifestyle modification in the form of diet was 
assumed as the mechanism of glucose lowering therapy. 
It was not possible to risk rate or classify patients by means of the Framingham risk 
scoring system as T2DM patients are already considered high risk i.e. necessitating 
secondary treatment.63  
According to the latest T2DM guidelines (see appendix vii) 48 56 57 58 T2DM patients:  
without previously established vascular disease (such as ischaemic heart disease, 
cerebrovascular disease or peripheral vascular disease), the LDL-C target of ≤2.5 
mmol/L is recommended.  
with established vascular disease (such as ischaemic heart disease, cerebrovascular 
disease or peripheral vascular disease), the LDL-C target of ≤1.8 mmol/L is 
recommended. 
For the purposes of this study, as per the latest guidelines (see appendix vii) 48 56 57 
58  the following thresholds were defined: 
Patients without previously established vascular disease were classified as “Lower 
Risk” and have an LDL-C target threshold: 2.5 mmol/L. 
Patients with established vascular disease were classified as “Higher Risk” and have 
an LDL-C target threshold: 1.8 mmol/L. 
For patients in both “lower risk” and “higher risk” not achieving LDL-C goals or 
targets as set by guidelines (see appendix vii), 48 56 57  using an adaptation from 
previous guideline studies, 64 65 LDL-C calculations for “Lower Risk” and “Higher risk” 
patients was conducted as follows:   
Mean “Off” Target level or “Gap” =  
The population mean of the patients not at goal (mmol/L) -   Guideline recommended LDL-C goal level (mmol/L)    X   100 
The population mean of the patients not at goal (mmol/L) 
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Mean “Off” Target level or “Gap” for “Lower Risk” Patients = 
The population mean of the patients not at goal (mmol/L) -   (2.5 mmol/L)   X   100 
The population mean of the patients not at goal (mmol/L) 
 
Mean “Off” Target level or “Gap” for “Higher Risk” Patients = 
The population mean of the patients not at goal (mmol/L) -   (1.8 mmol/L)   X   100 
The population mean of the patients not at goal (mmol/L) 
 
The results were calculated using the means and not the average of the means.  
When each individual was calculated separately and then the average of this was 
calculated, the difference (and percentage) is equivalent. 
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Statistical and Data Analysis 
 
A descriptive analysis was conducted which included summary measures, frequency 
tables and cross-tabulations. Means and standard deviations were calculated for the 
following: age, gender, race, blood pressures, glycated haemoglobins and fasting 
lipids. The percentage of previous CAD, stroke, nephropathy, neuropathy and 
retinopathy history in patients were also calculated including frequency of usage of 
chronic medication for the treatment of glucose, hypertension, lipids as well as 
receiving anti-platelet treatment. The percentage of patients reaching SEMDSA, 
ADA, IDF and ESC/EASD treatment goals for different clinical parameters was also 
tabulated.  
Cross-tabulations of summary measures by gender were done to investigate gender 
differences, if any. Chi-square test was used to investigate whether there were any 
statistically significant associations of these measures with gender. Where 
necessary, unpaired Student‟s t-test was used to compare mean differences. 
Shapiro-Wilk W test was performed to determine normality. If data was not normally 
distributed, the median and interquartile range (IQR) was reported. A linear 
regression model was fitted to look at gender differences adjusted for age. A 
significance level of 5% was used for all the statistical tests conducted.  
Microsoft Office Excel 2007 was utilised for the study‟s databases and statistical 
analysis was done using STATISTICA version 8.0.  
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Ethical Considerations 
 
Data from the CRF was entered into a secure database at the University Of 
Witwatersrand, Faculty of Health Science. 
Prior to the study, the Human Research Ethics Committee (HREC) granted ethical 
approval of the study. Ethics protocol number: M080409 (Figure 49). 
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RESULTS 
 
This observational study was conducted at the Charlotte Maxeke Johannesburg 
Academic Hospital between January 2008 and January 2010. In total, the records of 
785 patients were captured for the study. After applying study criteria to the captured 
data, the final cohort consisted of 666 patients. Exclusion criteria included having one 
or more of the following: patients having a positive diagnosis for type 1 diabetes 
mellitus, having gestational diabetes, steroid-induced diabetes or triglyceride levels > 
5 mmol/L. The cohort consisted of 666 patients of whom 369 (55%) were women. 
Ages ranged from 29 to 94 years, the mean age for the cohort was 63 (SD: 11.84) 
years.  
Demographics 
 
Using patient records at the Charlotte Maxeke Johannesburg Academic Hospital, 
CRF were completed. The ethnicity of the participants enrolled are shown in Table 2 
and Figure 1. 
 n % 
African 285 42.79 
Caucasian 196 29.43 
Asian 130 19.52 
Coloured 39 5.86 
Unknown 16 2.40 
Total 666 100.00 
 
Table 2 Ethnicity of type 2 diabetic study population 
 
One aim of the study was to document how well T2DM patients were being treated in 
a South African, public sector setting. The cohort comprised of patients initially 
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referred from their primary local clinics to a tertiary public sector clinic. This reflects 
the quality of care the state can provide, especially to those in the lower socio-
economic class who cannot afford private health care. 
 
Figure 1 Ethnicity of study type 2 diabetic population 
The total study cohort consisted of nearly half African population (42.79%). This 
study aimed to determine the level of care patients receive in South Africa, it may be 
said that the cohort breakdown is fairly representative of not only of patients 
receiving treatment in the public sector, but also that of the country‟s overall 
population.  
Ages 
 
The mean age for the cohort was 63 (SD: 11.86) years. The age range for the entire 
cohort was between 29 to 94 years and does not follow a Gaussian distribution 
(p<0.05), a median of 63 years (IQR = 54.00 – 70.00) was found. (Figure 2) 
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Figure 2 Age distribution of type 2 diabetic study cohort 
Mean ages by gender was almost identical, 62 (SD: 11.95) and 63 (SD 11.79) for 
men and women, respectively. 
Previously Established Cardiovascular Equivalent Conditions 
 
Events / Disease Occurrence 
Angina 17 
Angioplasty 3 
CABG 13 
CAD 9 
IHD 30 
Myocardial Infarct 13 
NSTEMI 1 
PVD 20 
Stent 2 
Stroke 16 
TIA 4 
Triple Bypass 1 
TOTAL 129 
 
Table 3 Total CVD-related events or disease amongst study type 2 diabetics; Coronary Artery 
Bypass Graft (CABG), Coronary Artery Disease (CAD), Ischaemic Heart Disease (IHD), Non-ST 
Segment Myocardial Infarction (NSTEMI), Peripheral Vascular Disease (PVD), Transient Ischemic 
Attack (TIA) 
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In total, there were 129 events or cardiovascular disease equivalent conditions. 
103/666 patients (15.5%) had macrovascular disease as some patients had multiple 
cardiovascular events/strokes. (Figure 3) 
 
Figure 3 % type 2 diabetics with previously established vascular disease; Coronary Artery 
Disease (CAD) 
 
 
 
 
 
 
 
 
 
84.53
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No CAD/Stroke CAD/Stroke
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In Figure 4, a statistically significant association between ethnicity and prevalence of 
cardiovascular disease was found (p<0.05). The Asian population had the highest 
rate of cardiovascular disease, in comparison, the Caucasian population had the 
second highest rate, but this was not statistically significant (Asian 25.38% vs. 
Caucasian 23.98%, p = 0.774). Despite having the highest count (n = 285, 
comprising 42.79% of the total cohort), the African population had the lowest rate of 
cardiovascular disease (5.00%). With only 39 patients comprising the Coloured 
population, 10.26% had some form of cardiovascular disease.   
 
Figure 4 Cardiovascular disease of study type 2 diabetics by ethnicity 
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Amongst the patients who had microvascular complications, nephropathy was the 
most common, affecting 78 patients (11.8%) of the cohort. This was followed by 47 
patients (7.1%) having neuropathy and 42 patients (6.4%) having retinopathy. Males 
had an apparently higher prevalence of both macro and microvascular complications, 
except retinopathy, but this was not statistically significant (male 5.4% vs. female 
7.1%, p = 0.382). By gender, there was no statistically significant differences for any 
of the other complications namely, CAD (male 17.2% vs. 11.9% female, p = 0.054), 
stroke (male 3.7% vs. 2.4% female, p = 0.343), nephropathy (male 12.5% vs. female 
11.1%, p = 0.592) and neuropathy (male 7.4% vs. female 6.8%, p = 0.752) (Figure 5). 
 
Figure 5 Microvascular and macrovascular disease across genders in type 2 diabetic study 
population; Coronary Artery Disease (CAD), females (F), males (M) 
There were 73 patients (11%) receiving thyroid medication and 47 patients (7.1%) 
were receiving medication for hyperuricemia. 
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Blood Pressure Control 
 
From the total cohort (666 patients), 569 (85.44%) were hypertensive and 97 
(14.56%) were normotensive. The mean SBP and DBP readings for the cohort were 
134 mmHg (SD: 20.0) and 79 mmHg (SD: 11.7), respectively. 
 
Figure 6 Total blood pressure readings of type 2 diabetic study population; Blood Pressure 
(BP) 
 
Five hundred and sixty nine patients (85.43% of the total 666 study population) were 
being treated for hypertension. From these, a portion had a positive history for 
diabetic nephropathy (which will ultimately affect their recommended BP targets). 
 
 n % 
Hypertensive without diabetic nephropathy 495 74.32 
Hypertensive with diabetic nephropathy 74 11.11 
Total Hypertensive Population 569 85.43 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
< 120 120 - 139140 - 159 ≥ 160 < 80 80-89 90-99 ≥100
Systolic BP Diastolic BP
%
 T
yp
e 
2
 D
ia
b
et
ic
 S
tu
d
y 
P
o
p
u
la
ti
o
n
 
Blood Pressure (mm Hg)
Type 2 diabetics
33 | P a g e  
 
 
Figure 7 % hypertension amongst type 2 diabetic study population 
 
The normotensive patients in the cohort had a mean SBP of 124 mmHg (SD: 13.0) 
and DBP of 75 mmHg (SD: 9.7). The hypertensive patients in the cohort had a mean 
SBP of 135 mmHg (SD: 20.5) and DBP of 78 mmHg (SD: 11.9). In comparison, there 
was a statistically significant difference between SBP (hypertensive 135 mmHg vs. 
normotensive 124 mmHg, p<0.01) and no statistically significant difference between 
DBP (hypertensive 78 mmHg vs. normotensive 75 mmHg, p = 0.070).  
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The hypertensive T2DM patients were receiving different numbers of 
antihypertensive drug classes as follows: 117 patients (17.57%), 177 patients 
(26.58%) and 275 patients (41.29%) were being treated with 1, 2 and ≥3 anti-
hypertensive drug classes, respectively (Figure 8).  
 
Figure 8 Number of antihypertensive medication classes taken by study type 2 diabetic 
population 
 
Most of the patients were on an ACE Inhibitor (79.96%). Diuretics were prescribed to 
397 patients (69.77%). Two hundred and sixty five patients (46.57%) were receiving 
calcium channel blockers and one-hundred patients (17.57%) were receiving β-
blockers. Especially with the two most frequently prescribed anti-hypertensive 
classes (ACE Inhibitors and Diuretics), it can be seen how combination therapy is 
prevalent amongst diabetics in the cohort (Figure 9). 
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Figure 9 % type 2 diabetic study population receiving different classes of antihypertensives 
 
In the cohort, females had slightly higher systolic blood pressure readings than males 
(female SBP 136 mmHg (SD: 19.4) vs. male SBP 132 mmHg (SD: 20.6)), p = 0.028). 
More females were being treated for hypertension (88.4% females vs. 81.9% males, 
p = 0.018) (Table 4). 
  Mean BP-SYS   Mean BP-DIAS   
Age Ranges M F M F 
30-39 125.60 127.83 75.00 79.83 
40-49 135.70 126.56 84.60 78.94 
50-59 135.36 134.78 81.13 79.70 
60-69 130.25 136.81 77.44 78.23 
70-79 133.82 139.63 75.36 77.26 
80-89 134.00 144.24 76.50 80.67 
90-99 130.00 155.00 80.00 70.00 
 
Table 4 blood pressure comparison amongst study type 2 diabetics; females (F), males (M) 
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For patients without documented diabetic nephropathy, the recommended 
SEMDSA/IDF treatment targets (SBP ≤130 mmHg; DBP ≤80 mmHg) were reached 
far more easily for DBP than SBP (DBP 69.1% vs. SBP 54.6%, p<0.01). Only 222 
(45.8%) reached the goals for both (Figure 10). 
 
Figure 10% type 2 diabetic study population without diabetic nephropathy achieving SEMDSA 
blood pressure goals 
 
In the study sample, seventy-four patients (11.11%) had documented nephropathy. 
These patients have stricter SEMDASA/IDF treatment targets (SBP ≤120 mmHg; 
DBP ≤70 mmHg). Only 25.5% of these patients achieved the SBP goal and 32.7% 
patients achieved the DBP goal (DBP 32.7% vs. SBP 25.5%, p = 0.013). Both SBP 
and DBP were achieved by 16.4% (Figure 11). 
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Figure 11 % type 2 diabetic study population with diabetic nephropathy achieving SEMDSA 
blood pressure goals; Systolic Blood Pressure (BP-SYS), Diastolic Blood Pressure (BP-DIAS), 
Blood Pressure (BP) 
Blood pressure goal achievement by number of antihypertensive classes taken (in 
patients without nephropathy) revealed that patients on monotherapy (i.e. one class 
of antihypertensive class) apparently achieved blood pressure goals more easily than 
those on antihypertensive combination therapy (Figure 12). 
 
Figure 12 % type 2 diabetic study population without nephropathy achieving SEMDSA blood 
pressure goals by number of drug classes; Systolic Blood (SYS), Diastolic Blood Pressure (DIAS), 
Blood Pressure (BP) 
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Goal attainment by number of antihypertensive drug classes in patients with 
nephropathy was not possible due to limitations in patient numbers.  
 
Patients without documented diabetic nephropathy who did not reach blood pressure 
SEMDSA target (≤130/80 mmHg) were analysed for the level at which they were not 
at goal (NAG). In Figure 10, it was apparent that fewer patients achieved target SBP 
than DBP. Further analysis of patients without nephropathy not reaching the 
SEMDSA blood pressure targets revealed that patients with uncontrolled SBP 
apparently were more uncontrolled by the first 10 mmHg more than any other range 
(SBP 47.3% (≤10 mmHg range) vs. SBP 27.8% (10-20 mmHg range), p<0.01) and 
(SBP 47.3% (≤10 mmHg range) vs.SBP 25.5% (≥20 mmHg range), p<0.01) (Figure 
13). Comparing uncontrolled levels of SBP and DBP, patients generally appear to 
follow a more balanced/equally distributed spread for SBP over all the ranges 
compared with DBP.  
 
Figure 13 % type 2 diabetic study population without nephropathy not at goal (130/80 mm Hg) 
by blood pressure ranges 
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Patients with documented diabetic nephropathy which did not reach SEMDSA goal 
for blood pressure (≤120/70 mmHg) were analysed for the level at which they were 
off goal (Figure 14). There were 48.65% of patients not reaching the 70 mmHg DBP 
target by ≤ 10 mmHg. A further 40.54% of patients had uncontrolled DBP by 10 – 20 
mmHg, whilst 10.81% of patients in the study were away from the DBP target of 70 
mmHg by ≥20 mmHg. There were equal numbers of patients in the study with 
uncontrolled levels of SBP in both the ≤10 mmHg and 10-20 mmHg ranges. There 
were 46.34% of patients with uncontrolled levels of SBP by ≥20 mmHg away from 
the desired SBP target of 120 mmHg.  
 
 
Figure 14 % type 2 diabetic study population with nephropathy not at goal (120/70 mm Hg) by 
blood pressure ranges 
 
From the total cohort, 12 patients (2.59%) did not meet either blood pressure targets 
and were not receiving anti-hypertensive treatment for this risk factor. 
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Glycaemic Control 
 
The mean HbA1c for the cohort was 8.8% (SD: 2.5). The HbA1c range was from 4.8% 
to 24.2%. HbA1c was not normally distributed (p<0.05) and the median was 8.1% 
(IQR = 7.00 – 10.10) (Figure 15). 
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Figure 15 HbA1c of study type 2 diabetic population; Glycated Haemoglobin (HbA1c) 
 
Ninety-nine patients (15.9%) had HbA1c of <6.5% in comparison to one-hundred and 
ninety three (31.0 %) which had HbA1c of 6.5%-8.0% (HbA1c <6.5% range vs. HbA1c 
6.5% - 8.0% range, p<0.01). Three hundred and thirty one patients (53.1%) had an 
HbA1c of >8% (HbA1c >8% range vs. HbA1c <6.5% range and HbA1c 6.5% - 8.0%, 
p<0.01 and p<0.01, respectively) (Figure 16). 
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Figure 16 HbA1c of study type 2 diabetic population; Glycated Haemoglobin (HbA1c) 
 
One hundred and forty five patients (23.3%) had a HbA1c of less than 7%. One 
hundred and forty six patients (23.4%) had an acceptable 7% - 8% range.Three 
hundred and thirty two patients (53.3%) had an HbA1c of >8% (where additional 
treatment needs to be initiated). There was no statistical difference between HbA1c 
<7% range vs. HbA1c 7-8% range, (p = 0.947), but there was a statistical difference 
between HbA1c >8 range vs. HbA1c <7% range and HbA1c 7-8% range (p<0.01  and 
p<0.01, respectively) (Figure 17). 
 
Figure 17 HbA1c of study type 2 diabetic population; Glycated Haemoglobin (HbA1c) 
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Females had slightly higher mean HbA1c than males (female 8.9% (SD: 2.6) vs. male 
8.5% (SD: 2.3)), but this was not statistically significant (p= 0.053) (Figure 18).  
 
Figure 18 Mean gender HbA1c comparison amongst study type 2 diabetics; Glycated 
Haemoglobin (HbA1c) 
Diet alone was used in 16 patients (2.4%). 196 patients (29.4%) were receiving oral 
hypoglycaemic therapy alone, 229 (34.4%) were on a combination of both oral 
hypoglycaemic and insulin therapy. 225 patients (33.8%) were receiving insulin alone 
(Figure 19).  
 
Figure 19 % type 2 diabetic study population receiving different hypoglycaemic therapy 
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Males apparently received more oral hypoglycaemic monotherapy (male 30.6% vs. 
female 28.5%, p = 0.591) and insulin monotherapy (male 36.7% vs. female 31.4%,   
p = 0.455), both not statistically significant. Females were more frequently on a 
combination of oral hypoglycaemic and insulin (female 37.9% vs. male 29.9%, p = 
0.031), which was statistically significant (Figure 20). 
 
Figure 20 Gender glucose therapy comparison amongst study type 2 diabetics 
 
Patients receiving insulin monotherapy had the highest HbA1c 9.40% (SD: 2.6) whilst 
patients on insulin and hypoglycaemic combination therapy had an HbA1c of 9.11% 
(SD: 2.3), (HbA1c insulin monotherapy 9.40% vs. HbA1c combination therapy 9.11%, 
p = 0.097). Patients being treated with oral hypoglycaemics alone had an HbA1c of 
7.67% (SD: 2.0), whilst, the lowest HbA1c of 6.25% (SD: 1.0) was present in patients 
on diet alone (HbA1c oral hypoglycaemics 7.67% vs. HbA1c diet alone 6.25, p = 0.007)    
(Figure 21). 
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Figure 21 Mean HbA1c of type 2 diabetic study population by glucose-lowering therapy; 
Glycated Haemoglobin (HbA1c) 
 
The study population used three classes of oral hypoglycaemics, namely Biguanides, 
Sulphonylureas and Thiazolidinediones. Three hundred and ninety seven patients 
(70%) were receiving Biguanides, one hundred and sixty two patients (29%) were 
receiving Sulphonylureas whilst four patients were on Thiazolidinediones (1%) (Figure 
22). 
 
Figure 22 Type 2 diabetic study population receiving different oral hypoglycaemic therapy 
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The number of oral hypoglycaemics classes taken by study patients varied: 284 
(66.8%) received one class, 139 (32.7%) received two classes and 2 patients (0,5%) 
received three classes (Figure 23).  
 
Figure 23 Number of oral hypoglycaemic medication classes taken by study type 2 diabetic 
population 
 
Further analysis revealed that monotherapy with Biguanides (namely Metformin 
850mg) were the most common form of oral hypoglycaemic taken, as they were 
taken by 261 patients (61.5%) (Biguanides vs. Biguanides / Sulphonylurea 
combination and Sulphonylurea monotherapy, p<0.01 and p<0.01, respectively). 
Biguanides / Sulphonylurea combination was taken by 134 patients (31.6%). 
Sulphonylurea monotherapy was taken by 25 patients (5.9%). There were 5 patients 
(1%) taking a Thiazolidinedione (either Pioglitazone or Rosiglitazone) (Figure 24). 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
1 2 3
%
 T
yp
e
 2
 D
ia
b
et
ic
 P
o
p
u
la
ti
o
n
Number Of Oral Hypoglycaemic Classes
Type 2 Diabetics
46 | P a g e  
 
 
Figure 24 Classes of oral hypoglycaemic medication taken by study type 2 diabetic population 
 
From the 454 patients (68.17%) receiving insulin, 390 patients were receiving one 
class of insulin, whilst 64 patients were on a combination of two insulins, (one class 
of insulin vs. combination insulin, p<0.01) (Figure 25). 
 
Figure 25 Number of insulins used by study type 2 diabetic population 
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Of the total number of patients receiving insulin (be it mono- or combination therapy), 
317 patients were receiving intermediate-acting (Actraphane ® and Humulin ®), 122 
patients were receiving long-acting (Protaphane ®), 75 patients were receiving short-
acting (Actrapid ®) whilst 4 patients were receiving rapid acting insulin (Humalog ® 
and Novorapid ®)(Figure 26). 
 
Figure 26 Types of insulin used by study type 2 diabetic population 
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In the cohort, 163 patients (26.2%) reached the SEMDSA/ADA treatment target 
(HbA1c≤7 %) in comparison to the 107 patients (17.2%) which reached the 
EASD/ESC/IDF treatment target (HbA1c≤ 6.5 %). SEMDSA/ADA treatment target 
HbA1c≤7 % vs. EASD/ESC/IDF treatment target HbA1c≤ 6.5 %, p<0.05 (Figure 27). 
 
Figure 27 % type 2 diabetic study population achieving HbA1c goals by various guidelines; 
Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA), American Diabetes 
Association (ADA), International Diabetes Federation (IDF) and European Society of Cardiology / 
European Association for the Study of Diabetes (ESC/EASD), Glycated Haemoglobin (HbA1c) 
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Patients who did not reach SEMDSA goal for HbA1c (≤7%) were analysed for the 
level at which they were off goal. One hundred and sixty patients (33.5%) were off 
goal by ≥3%, making it slightly higher than the one hundred and forty-seven patients 
(30.6%) which were off target by ≥1%, (≥3% range vs. ≥1% range, p<0.01). 
Combining the two middle ranges (patients that off goal by 1-3%) would yield a new 
majority (35.9%) of patients off goal (Figure 28).  
 
 
Figure 28 % type 2 diabetic study population not at goal (7%) by HbA1c ranges; Glycated 
Haemoglobin (HbA1c) 
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A gender comparison of patients off SEMDSA HbA1c target revealed that males were 
apparently more off target than the females in the ≤1% and 2-3% range (male 32.7% 
vs. female 29.0%, not statistically significant, p = 0.634) and (male 16.1% vs. female 
14.3%, not statistically significant, p = 0.605), respectively. Females were more 
apparently off target in the 1-2% and ≥3% range (male 19.0% vs. female 22.1%, not 
statistically significant, p = 0.259) and (male 32.2% vs. female 34.6%, not statistically 
significant, p = 0.823), respectively (Figure 29). 
 
 
Figure 29 % type 2 diabetic study population not at goal (7%) by gender-HbA1c ranges; females 
(F), males (M), Glycated Haemoglobin (HbA1c) 
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A gender-age comparison of patients off SEMDSA HbA1c target (>7%) demonstrates 
that 50.8% and 43.8% of the youngest males and female patients (≤55 years) were 
apparently off target by HbA1c ≥3%, respectively. Most trends follow an apparently 
similar pattern except for the youngest males (≤55 years) in the 1-2% off target range 
(Figure 30). 
 
Figure 30 Comparison showing type 2 diabetics off SEMDSA HbA1c target (7%) using gender-
age (years) groupings; females (F), males (M) 
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Lipid Control 
 
The lipid readings for the entire population were 4.6 mmol/L (SD: 1.2), 1.8 mmol/L 
(SD: 1.0), 1.2mmol/L (SD: 0.4) and 2.6 mmol/L (SD: 0.9) for TC, TG, HDL-C and 
LDL-C respectively. 
 
Females had slightly higher TC than males (female 4.8 mmol/L (SD: 1.11) vs. male 
4.5 mmol/L (SD: 1.2), p<0.05) as well as higher HDL-C (female 1.3 mmol/L (SD: 0.4) 
vs. male 1.1 mmol/L (SD: 0.4), p<0.05). Males had similar TG to the females, whilst 
females had higher LDL-C, both not significant (Figure 31).  
 
Figure 31 Lipid mean comparison of type 2 diabetic study population by gender; total 
cholesterol (TC), triglycerides (TG), High Density Lipoprotein Cholesterol (HDL-C), Low Density 
Lipoprotein Cholesterol (LDL-C), females (F), males (M) 
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The analysis of mean LDL-C reduction needed (from 2.5 mmol/L) by gender-age 
groups for patients without previous CAD/Stroke revealed some interesting results. 
Males required a larger reduction than the females in both the ≤55 year (male 0.99 
mmol/L vs. female 0.92 mmol/L, not statistically significant, p = 0.928) as well as in 
the 55 – 65 year group (male 0.84 mmol/L vs. female 0.72 mmol/L, not statistically 
significant, p = 0.794). The females in the ≥65 year group required a larger reduction 
than the males (female 0.75 mmol/L vs. male 0.64 mmol/L, not statistically 
significant, p = 0.556) (Figure 32). 
 
 
Figure 32 LDL-C reduction needed for study type 2 diabetics without previous CAD/stroke (2.5 
mmol/L) by gender-age grouping; Coronary Artery Disease (CAD), females (F), males (M), Low 
Density Lipoprotein Cholesterol (LDL-C) 
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An analysis of mean LDL-C reduction (from 1.8 mmol/L) needed by gender-age 
groups for patients with previous CAD/Stroke was conducted. Females in the ≤55 
age group required a larger reduction in LDL-C than the males (female 1.52 mmol/L 
vs. 1.39 mmol/L, not statistically significant p = 0.869). Males required a greater 
reduction in the 55-65 age group (male 1.22 mmol/L vs. female 0.86 mmol/L, 
statistically significant, p = 0.023) as well as in the ≥65 age group (male 1.05 mmol/L 
vs. female 1.02 mmol/L, not statistically significant, p = 0.992) than the females 
(Figure 33). 
 
Figure 33 LDL-C reduction needed for study type 2 diabetics with previous CAD/stroke (1.8 
mmol/L) by gender-age grouping; Coronary Artery Disease (CAD), females (F), males (M), Low 
Density Lipoprotein Cholesterol (LDL-C) 
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TC target was reached by 320 patients (53.8%) (≤ 4.5 mmol/L SEMDSA/ADA), 348 
patients (60.2%) reached the TG target (≤ 1.7 mmol/L SEMDSA / ADA goal). 150 
males (58.6%) reached the male SEMDSA/ADA HDL-C targets (≥1 mmol/L) whilst 
171 and 141 female patients reached the SEMDSA (≥1.2 mmol/L) and ADA (>1.3 
mmol/L) HDL-C targets (52.8% vs. 43.5%, p<0.05), respectively. More patients 
reached ADA LDL-C goal compared with SEMDSA goal (57.6% vs. 53.8%, p = 
0.173) as the latter target was slightly harder to achieve (ADA goal 2.6mmol/L vs. 
SEMDSA goal 2.5mmol/L) for patients without previous CAD or stroke. For patients 
with previous CAD or stroke, 17 patients (17.9%) reached targets (1.8 mmol/L 
SEMDSA / ADA goal) (Figure 34).  
 
Figure 34 % type 2 diabetic study population achieving lipid goals as set by SEMDSA and ADA 
guidelines; High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-
C), Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA), American 
Diabetes Association (ADA), Coronary Artery Disease (CAD) 
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From the total cohort (666 patients), 275 patients (46.2%) had hypercholesterolaemia 
and 230 patients (39.8%) had hypertriglyceridaemia. Three hundred and forty five 
patients (51.8%) were being treated with HMG-CoA Reductase Inhibitors (statins) 
lipid-lowering drugs (Figure 35). More females were being treated with statin lipid-
lowering therapy than males (male 56.9% vs. female 61.3%, not statistically 
significant, p = 0.449), whilst the opposite was seen with fibrate therapy (male 15.5% 
vs. female 9.8%, statistically significant, p = 0.025). 
 
Figure 35 % type 2 diabetics of total study population receiving and not receiving statin lipid-
lowering therapy 
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Analysis of patients with and without CVD revealed that 289 patients (51.3%) without 
previous CAD/Stroke were not receiving statin lipid-lowering therapy for primary 
prevention purposes. For patients with previous CVD, 32 patients (31.1%) were not 
being treated for secondary prevention purposes with statin lipid-lowering therapy 
(primary prevention 51.3% vs. secondary prevention 31.1%, p<0.05) (Figure 36).  
 
Figure 36 % study type 2 diabetics with or without CAD/stroke receiving or not receiving statin 
lipid-lowering therapy; Coronary Artery Disease (CAD) 
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Patients without previous CAD/Stroke receiving statin lipid-lowering therapy had 
higher mean LDL-C than those not receiving lipid-lowering therapy (2.60 mmol/L 
(SD: 0.97) vs. 2.53 mmol/L (SD: 0.80), p = 0.408), respectively. The same was seen 
in patients with previous CAD/Stroke (2.71 mmol/L (SD: 0.91) vs. 2.54 mmol/L (SD: 
1.09), p = 0.441), respectively (Figure 37).  
 
In patients receiving statin lipid-lowering therapy, those with previous CAD/Stroke 
had higher mean LDL-C than without previous CAD/Stroke (2.71 mmol/L (SD: 0.91) 
vs. 2.60 mmol/L (SD: 0.97), not statistically significant, p = 0.415), respectively. A 
similar pattern followed with patients not receiving statin lipid-lowering therapy (p = 
0.934) (Figure 37).   
 
Figure 37 Mean LDL-C of study type 2 diabetics with or without CAD/stroke; Low Density 
Lipoprotein Cholesterol (LDL-C), Coronary Artery Disease (CAD) 
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The mean LDL-C of patients achieving SEMDSA goal without previous CAD/Stroke 
was 1.49 mmol/L (SD: 0.3) whilst those with previous CAD/Stroke, 1.42 mmol/L (SD: 
0.4), (1.49 mmol/L vs. 1.42 mmol/L, not statistically significant, p = 0.421). Patients 
not achieving goal and without previous CAD/Stroke had an LDL-C of 3.31 mmol/L 
(SD: 0.7), less than the 3.37 mmol/L (SD: 0.7) LDL-C of those patients with previous 
CAD/Stroke (3.31 mmol/L vs. 3.37 mmol/L, not statistically significant, p = 0.602) 
(Table 5). 
 
 
 
SEMDSA LDL-C 
Goals (2.5mmol/L) 
(No Previous 
CAD/Stroke) 
 
(mmol/L) 
SEMDSA LDL-C 
Goals (1.8mmol/L) 
(Previous 
CAD/Stroke) 
 
(mmol/L) 
LDL-C Achieving Goal 1.49 (SD: 0.3) 1.42 (SD: 0.4) 
LDL-C NOT Achieving Goal 3.31 (SD: 0.7) 3.37 (SD: 0.7) 
 
Table 5 Mean LDL-C levels of study type 2 diabetic population; Low Density Lipoprotein 
Cholesterol (LDL-C), Coronary Artery Disease (CAD), Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA) 
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Figure 39 % type 2 diabetics achieving 
SEMDSA LDL-C goals (1.8 mmol/L) 
 
Figure 38 % type 2 diabetics achieving 
SEMDSA LDL-C goals (2.5mmol/L) 
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Patients without previous CAD/Stroke were off LDL-C target (2.5mmol/L) by an 
average of 0.81 mmol/L. Patients with previous CAD/Stroke were off LDL-C target 
(1.8mmol/L) by an average of 1.13 mmol/L, (patients without previous CAD/Stroke 
0.81 mmol/L vs. patients with previous CAD/Stroke 1.13 mmol/L, p<0.01).   (Figure 
40). 
 
Figure 40 Mean LDL-C Off Target levels for study type 2 diabetic population with and without 
previous CAD/Stroke; Low Density Lipoprotein Cholesterol (LDL-C), Coronary Artery Disease 
(CAD), previous (prev), Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA) 
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Figure 41 demonstrates the comparison of patients achieving SEMDSA targets by 
either receiving or not receiving statin lipid lowering therapy. Patients without 
previous CAD/Stroke reached LDL-C targets (2.5 mol/L) more frequently using statin 
lipid lowering therapy (statin 53.28% vs. non-statin 46.72%, not statistically 
significant, p = 0.620) and the same was seen in patients with previous CAD/Stroke 
(statin 52.94% vs. non-statin 47.06%, not statistically significant p = 0.059) for LDL-C 
targets (1.8 mmol/L). 
 
 
Figure 41 % type 2 diabetics achieving SEMDSA LDL-C goals by lipid-lowering therapy; 
previous (prev), Low Density Lipoprotein Cholesterol (LDL-C), Coronary Artery Disease (CAD), 
Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
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Patients which did not achieve LDL-C targets were analysed (Figure 42). Those who 
had no previous CAD/Stroke followed a consistent pattern; most count of patients 
(n=69) were off target by ≤10% and the least count of patients (n=9) were off by 
≥51% from target LDL-C (2.5 mmol/L) (≤10% group vs. ≥51% group, P<0.01). 
Patients with previous CAD/Stroke were most off target by 21-30% and 41-50% 
equally (both 23.38%), whilst least off target by ≤10% (21-30% and 41-50% group 
23.38% vs. ≤10% group 6.49%, p<0.01).  
 
Figure 42 % type 2 diabetic patients away from LDL-C goal; Low Density Lipoprotein Cholesterol 
(LDL-C), Coronary Artery Disease (CAD), Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA)  
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From the 345 patients (51.8%) being treated with statin lipid-lowering drugs, 45 
patients (13.0%) were receiving 10mg Simvastatin, 204 patients (59.1%) were 
receiving 20mg Simvastatin, 77 patients (22.3%) were receiving 40mg Simvastatin 
and 8 patients (2.3%) were receiving 40mg Atorvastatin (simvastatin 20mg vs. 
simvastatin 10mg, simvastatin 40mg and atorvastatin 40mg, p<0.01, p<0.01 and 
p<0.01, respectively) . 11 patients (3.2%) were receiving other tailored doses of 
Simvastatin and Atorvastatin (Figure 43).  
 
 
Figure 43 Type and dosage of statin therapy in study type 2 diabetic population; milligrams (mg) 
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In the following, patients either achieving or not achieving LDL-C SEMDSA targets by 
statin classes and dosages were analysed. Study patients were classified by either 
lower-risk (Figure 44) or higher-risk (Figure 45).  
 
Patients without previous CAD/Stroke (lower-risk) were analysed to see if they were 
achieving SEMDSA LDL-C target (2.5 mmol/L). There were more counts of patients 
(n = 54) off target (LDL-C 2.5 mmol/L) using 20mg Simvastatin than any other statin 
(simvastatin 20mg 54 patients vs. simvastatin 10mg 16 patients, simvastatin 40mg 
31 patients and atorvastatin 40mg 3 patients, p<0.01, p<0.01 and p<0.01, 
respectively). The highest % of patients off target (LDL-C 2.5 mmol/L) by statin 
dosage were those using 40mg Simvastatin (64.6%) followed by those using 
Atorvastatin 40mg (60.0%), but this was not statistically significant (p = 0.076) (Figure 
44). 
 
Figure 44 % type 2 diabetics without previous CAD/stroke reaching SEMDSA goal (2.5mmol/L) 
using different statin classes and dosages; Not At Goal (NAG), At Goal (AG), Atorvastatin 
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(Atorva), Simvastatin (Simva), Not At Goal (NAG), milligrams (mg), Society for Endocrinology, 
Metabolism and Diabetes of South Africa (SEMDSA) 
 
For patients with previous CAD/Stroke (higher-risk), most patients were off target 
across all statin classes and dosages (Figure 45). By count, more patients were off 
target (LDL-C 1.8 mmol/L) using 20mg Simvastatin than any other class or dosage of 
statin (n = 29) (simvastatin 20mg 29 patients vs. simvastatin 10mg 1 patient, 
simvastatin 40mg 23 patients and atorvastatin 40mg 1 patient, p<0.01, p<0.01 and 
p<0.01, respectively). In Figure 45, all patients receiving 40mg Atorvastatin and 10mg 
Simvastatin were off LDL-C target (LDL-C 1.8 mmol/L).  
 
Figure 45 % type 2 diabetics with previous CAD/stroke reaching SEMDSA goal (1.8 mmol/L) 
using different statin classes and dosages; Not At Goal (NAG), At Goal (AG), Atorvastatin 
(Atorva), Simvastatin (Simva), Not At Goal (NAG), milligrams (mg), Society for Endocrinology, 
Metabolism and Diabetes of South Africa (SEMDSA) 
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An analysis of patients NAG for both SEMDSA LDL-C targets (1.8 mmol/L and 2.5 
mmol/L for patients with and without CAD/stroke, respectively) demonstrated the 
overall average LDL-C for patients receiving statin lipid-lowering therapy by class 
and dosage (Figure 46). Patients on 40mg atorvastatin (without previous CAD/Stroke) 
apparently had the highest LDL-C (4.07 mmol/L), whilst those on simvastatin 10mg 
(with previous CAD/Stroke) apparently had the lowest LDL-C (1.90 mmol/L), (40mg 
atorvastatin LDL-C 4.07 mmol/L vs. 10mg simvastatin LDL-C 1.90 mmol/L, p<0.01). 
 
Figure 46 Mean LDL-C for study type 2 diabetic patients NAG for SEMDSA targets using 
different statin lipid lowering therapy; Atorvastatin (Atorva), Simvastatin (Simva), Not At Goal 
(NAG), Coronary Artery Disease (CAD), milligrams (mg), Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA) 
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Patients with or without cardiovascular disease have different LDL-C goals to reach 
as set by both national and international guidelines. Patients in the study receiving 
statin lipid-lowering therapy and not at SEMDSA LDL-C goal were analysed. Using 
the “rule of six” where there is a further 6% LDL-C reduction for every doubling of 
statin dosage, we hypothetically calculated how many patients in the cohort off target 
would require their current statin dosage increased in order to achieve goal. The “rule 
of six” can be applied to doubling, tripling or even possibly doubling the statin dosage 
twice in order to achieve a 6%, 6-12% or 12-18% LDL-C reduction, respectively.  
 
Patients further off goal (>18%) may require adding Ezetimibe to their current statin. 
When combining 10mg Ezetimibe to a statin (at any dosage), there is an 
approximate 20-25% LDL-C reduction. Similarly as done with the “rule of six”, we 
hypothetically calculated how many patients in the cohort off target would require 
Ezetimibe added to their current statin in order to achieve goal. In order to achieve 
LDL-C, certain patients would require a change of statin class all together, thereby 
necessitating the much-needed greater reduction in LDL-C. Table 6 shows the 
number of patients who are eligible for either a dosage increase, addition of 
Ezetimibe or both. 
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Table 6 Study type 2 diabetics not achieving goal and receiving statin lipid-lowering therapy; 
Coronary Artery Disease (CAD), Low Density Lipoprotein Cholesterol (LDL-C) 
 
 
 
 
Away From LDL-C 
Goal 
(%) 
NO CAD/Stroke 
n (%) 
CAD/Stroke 
n (%) 
Action 
Required 
≤6 7 (6.5%) 2 (3.5%) 
Double Statin 
Dose 
6 - 12 26 (24.1%) 2 (3.5%) 
Triple Statin 
Dose 
12 - 18 13 (12.0%) 7 (12.3%) 
Double Statin 
Dose (twice) 
18 - 25 14 (13.0%) 10 (17.5%) Add Ezetimibe 
≥25 48 (44.4%) 36 (63.2%) 
Add Ezetimibe 
and Double 
Statin Dose 
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Without the use of lipid-lowering therapy, results from the data indicate that 114 
patients (51.4%) without previous CAD/Stroke, as well as 20 patients (26.0%) with 
previous CAD/Stroke were off LDL-C target (≤2.5 mmol/L and ≤1.8 mmol/L, 
respectively). In order for patients to reach LDL-C goal, it may be necessary to 
commence lipid-lowering therapy. Table 7 demonstrates the % reduction needed for 
patients off LDL-C goal by recommended class and dosage of different statins 
currently available on the market. This of course is a hypothetical exercise and can 
only be used to indicate which possible statin would be ideal for patients only based 
on their LDL-C. Patients off LDL-C target should be placed on suitable lipid-lowering 
therapy subject to many factors such as and (not limited to) tolerance of side-effects 
and possible drug interactions with other concurrent therapy. 
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Away From 
LDL-C Goal 
(%) 
NO 
CAD/Stroke 
n (%) 
 
CAD/Stroke 
n (%) 
Recommended Statin 
Dosage 
(mg) 
LDL-C 
Reduction 
Expected 
(%) 
≤ 10 23 (20.2%) 1 (5.0%) 
Same as for 10 – 20% 
away from LDL-C goal 
group (below) 
- - 
10 - 20 52 (45.6%) 2 (10.0%) Pravastatin 10 18-25 
20 - 30 19 (16.7%) 4 (20.0%) 
Lovastatin 10 21 
Fluvastatin 20 22 
Fluvastatin 40 25 
Pravastatin 10 18-25 
Lovastatin 20 24-27 
Pravastatin 20 23-29 
Simvastatin 10 26-33 
Pravastatin 40 26-34 
30 - 40 13 (11.4%) 1 (5.0%) 
Fluvastatin 80 35 
Pravastatin 80 30-37 
Atorvastatin 10 34-38 
Simvastatin 20 30-40 
40 - 50 4 (3.5%) 8 (40.0%) 
Ezetimibe/Simvastatin 10/10 45 
Simvastatin 40 35-45 
Rosuvastatin 5 39-46 
Atorvastatin 20 42-46 
Lovastatin 80 39-48 
Simvastatin 80 40-50 
Rosuvastatin 10 43-50 
50 - 60 3 (2.6%) 3 (15.0%) 
Atorvastatin 40 47-51 
Ezetimibe/Simvastatin 10/20 52 
Atorvastatin 80 46-54 
Ezetimibe/Simvastatin 10/40 55 
Rosuvastatin 20 52-55 
Ezetimibe/Atorvastatin 10/10 53 
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Ezetimibe/Atorvastatin 10/20 54 
Ezetimibe/Atorvastatin 10/40 56 
≥ 60 0 (0.0%) 1 (5.0%) 
Ezetimibe/Simvastatin 10/80 ≥60 
Ezetimibe/Atorvastatin 10/80 ≥60 
Ezetimibe/Rosuvastatin 10/All ≥60 
 
Table 7 Current statin therapy lipid-lowering therapy available to study type 2 diabetics off 
LDL-C target; Low Density Lipoprotein Cholesterol (LDL-C), Coronary Artery Disease (CAD), 
milligram (Mg)  
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Blood Pressure, Glycaemic Control and Lipids Targets 
 
The combination of all three targets - HbA1c (≤7%), Blood Pressure (≤130/80 mmHg) 
and LDL-C (≤ 2.5 mmol/L) revealed that 27/362 patients (7.5%) were at goal for the 
above mentioned targets. Furthermore, a comparison of the results with other 
international guideline studies produced some interesting results. (Table 8)   
 
 
Study 
 
(No) 
Guideline 
Applied 
 
 
Glycaemic 
Control 
(HbA1c) 
 
(%) 
Blood 
Pressure 
(SBP/DBP) 
 
(%) 
Lipids 
(LDL-C or 
TC) 
 
(%) 
All Targets  
 
(%) 
Current 
SEMDSA 
2009 
26.2 45.8* 53.8** 7.5 
1 
SEMDSA 
2003 
30.7 
21.3 (SBP) 
40.2 (DBP) 
50.7 - 
2 
SID 2002  
ADA 2007 
ESC/EASD 
2007 
37.0 10.3 16.5 5.0 
3 IDF 1999 35.0 52.0 32.0 6.0 
4 ADA 2003 41.0 
27.0 (SBP) 
72.0 (DBP) 
41.0 0.0 
5 ADA 2003 39.0 14.0 27.0 1.0 
 
Table 8 % patients achieving goals in other studies; Glycated Haemoglobin (HbA1c), Systolic Blood 
Pressure (SBP), Diastolic Blood Pressure (DBP), Low Density Lipoprotein Cholesterol (LDL-C), Total 
Cholesterol (TC) 
*Diabetics without nephropathy achieving SEMDSA goal (≤130/80 mmHg) ** Diabetics without previous 
CAD/Stroke achieving SEMDSA goal (≤2.5 mmol/L) 
 
Guideline Study 
 
 
Current: The Implementation Of Current Guidelines Regarding The Treatment Of 
Cardiovascular Risk In Type 2 Diabetics 
 
1. Sub-Optimal Management Of Type 2 Diabetes Mellitus - A Local Audit.55 
 
2. The clinical reality of guidelines for primary prevention of cardiovascular 
disease in type 2 diabetes in Italy.49  
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3. The gap between guidelines and practice in the treatment of type 2 diabetes – 
A nationwide survey in Norway.51  
 
4. Cardiovascular risk factors in patients with type 2 diabetes – Do we follow the 
guidelines? 52 
 
5. Can the atherosclerosis prevention targets be achieved in type 2 diabetes? 53   
 
 
 
 
 
 
 
Figure 47 % study type 2 diabetics at SEMDSA goal for glycaemia, blood pressure and lipids; 
Glycated Haemoglobin (HbA1c), Low Density Lipoprotein Cholesterol (LDL-C), Blood Pressure (BP) 
  
26.2%
HbA1c ≤7%
45.8%
BP ≤130/80 
mm Hg
53.8%
LDL ≤2.5 
mmol/L
7.5% 
12.6% 
23.1% 
16.5% 
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There were 229/563 patients receiving anti-platelet therapy for primary prevention 
purposes whilst 56/103 patients were receiving for secondary prevention (primary 
prevention 40.7% vs. secondary prevention 54.4%, p= 0.013) (Figure 48). 
 
Figure 48 Antiplatet therapy in study type 2 diabetic population with & without CAD/stroke; 
Coronary Artery Disease (CAD)   
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DISCUSSION 
 
Type 2 Diabetes Mellitus is frequently accompanied by obesity. 66 A 2003 South 
African epidemiological study revealed that as much as 29% of men and 56% of 
women were classified as overweight or obese.67 As the South African population 
becomes urbanised and more affluent, diseases of lifestyle such as T2DM have 
proliferated in a similar fashion. The most recent South African mortality patterns 
reveal a 41% increase due to non-communicable diseases such as CVD.68 Evidence 
linking CVD and T2DM is strong, CVD being the primary cause of mortality in these 
patients.69 According to the Framingham Heart study, diabetics have a 2-3 times 
higher risk of cardiovascular events than non-diabetics.63 Clearly South Africa faces 
many threats on the health care front, but T2DM is growing alarmingly.  
 
Although hyperglycaemia is undoubtedly a risk factor for microvascular 
complications, intensive glycaemic management has delivered only modest 
improvements in macrovascular endpoints thus far. A multidisciplinary approach 
addressing all the components of the dysmetabolic syndrome, including insulin 
resistance, dyslipidaemia, hypertension, obesity and impaired fibrinolysis, will be 
required to protect the cardiovascular system more effectively. 70 
 
In T2DM, treatment needs be multidimensional. The landmark UKPDS trial 
demonstrated that glycaemic control alone was not enough to reduce the fatal 
consequences of CVD.9 Only through the implementation of guidelines that target 
additional cardiovascular risk factors such as blood pressure and lipids that 
significant reduction in mortality in these patients can be achieved.   
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In 1996, Raal et al. conducted an audit in the Johannesburg Academic Hospital with 
82 diabetic patients.54 The objectives were to measure the management of 
cardiovascular risk factors in T2DM patients. Outcomes revealed that diabetic 
management was primarily aimed at glycaemic control alone. In 2006, 50 patients 
were audited for similar parameters at the same location. 71 Results from this study 
revealed that not much had changed over ten years and that a significant gap in the 
management of cardiovascular risk factors in T2DM still existed.  
 
Using the latest SEMDSA, IDF, ESC/EASD and ADA T2DM guidelines, the present 
study aimed to further investigate management of South African T2DM patients in a 
public sector setting. 
 
Blood Pressure 
 
Hypertension is common amongst T2DM patients.72 The present study had 569 
hypertensive patients (85.4%). Importance of management of blood pressure in 
T2DM has been recognised by national 56 and international 48 57 58 guidelines; yet 
reaching these targets remains difficult.73 Almost half the cohort (45.8%) reached 
SEMDSA ≤130/80 mmHg targets (no nephropathy), less patients with nephropathy 
(16.4%) reached targets of ≤120/70 mmHg.  
 
The current study, where almost half the patients (45.8%) without nephropathy 
reached SEMDSA ≤130/80 mmHg targets is comparable to the 52.0% of patients 
which reached targets of <140/85 mmHg as set by the previous IDF 1999 guidelines 
in a separate Norwegian study.51 Had patients in the current study been measured 
against “less stricter” blood pressure targets of 140/85 mmHg as those set by the 
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previous guidelines, then certainly more patients would at goal. Only 14.0% and 
10.3% of patients achieved blood pressure targets of ≤130/80 in a Czech and an 
Italian study, respectively.53 49 With so few patients reaching blood pressure targets, 
perhaps patients comprising the cohorts of the Czech and Italian studies were more 
complicated or further burdened with disease in comparison with the current and 
Norwegian study. 
 
The benefits of tight blood pressure are comparable with the benefits of tight 
glycaemic control in T2DM. In the landmark United Kingdom Prospective Diabetes 
Study (UKPDS) where 1148 hypertensive T2DM patients were assigned to either 
captopril or atenolol, there was a significant reduction in the risk of both fatal and 
non-fatal macrovascular and microvascular complications.42 In the same year, using 
felodipine, there were similar findings in the Hypertension Optimal Treatment (HOT) 
study.74 Both trials demonstrated the benefits of blood pressure reduction in T2DM 
patients and the suggestion of “the lower the better” became unmistakable.  
 
For both patients with and without documented diabetic nephropathy in the cohort, 
DBP goal was reached more easily than SBP. DBP was once seen as the chief 
parameter for hypertension diagnosis, staging and as the antihypertensive drug 
efficacy index. Data from the latest trials suggests that “both SBP and pulse pressure 
are better predictors of CVD than DBP” as “increased SBP and pulse pressure are 
closely related and usually represent increased stiffness of large arteries, which is 
associated with increased prevalence of CVD and increased cardiac mortality.” 75 
Also, it has been documented that raised SBP is indicative of stroke mortality. 76  
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In the current cohort, the majority of hypertensive patients (without nephropathy) 
were receiving ≥3 anti-hypertensive drug classes. Goal attainment was more 
prevalent in patients using mono therapy (58.2% vs. 43.7% vs. 34.4% achieved 
targets using 1, 2 and ≥3 anti-hypertensive drug classes, respectively). Similar 
outcomes were seen in a 2009 Canadian study.72 It is possible that the monotherapy 
group achieved targets more easily as in the likely case of patients with less severe 
hypertension or a shorter duration of diabetes (less burdened with disease). 77 One 
study advocates that an average of 2.9 medicines per patient is necessary in order to 
achieve BP targets.78 In the intensive treatment arm of the UKPDS study, 29% of 
patients greatly benefited from treatment with at least 3 classes of antihypertensives. 
42 Dosage adjustments will affect BP reduction levels and drug side-effects may 
impact patient compliance.  An analysis of 354 randomized trials demonstrated that 
combination therapy using half the standard dose produces an additive BP lowering 
effect with the benefit of side-effect reduction. 79 Perhaps dosage reductions in 
addition to combination therapy are the way forward in order to achieve the best 
blood pressure goals. 
 
The UKPDS demonstrated that adequate blood pressure control can lower incidence 
of developing microvascular complications such as nephropathy.42 The most 
commonly prescribed antihypertensive drug class in the study were ACE-Inhibitors 
(79.96%) followed by diuretics (69.8%). As per the SEMDSA guidelines, ACE-I are 
recommended as first line therapy for hypertensive diabetics, especially in those 
patients with microalbuminuria or pre-existing CVD.56  With almost 30% of patients 
with diabetic nephropathy progressing to ESRF,80 the use of ACE-Inhibitors in T2DM 
has significant benefit. ACE-I are particularly useful over other antihypertensive drug 
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classes through delay of the onset or progression of nephropathy and reduction in 
the progression from micro to macroalbuminuria. 81 82 83 
 
Diuretics were the second most commonly prescribed drug class in the cohort and 
this mainly comprised of thiazide diuretics. There has been data which has 
suggested the role of thiazide diuretics in the cause diabetes. In the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study, 84 
patients receiving chlorthalidone had a higher incidence of diabetes onset compared 
with amlodipine and lisinopril (11.6% vs. 9.8% vs. 8.1%, respectively). However, no 
hypertension drug study to date has used diabetes onset as a primary end point, 
leaving the question open until proven otherwise with more definitive evidence.  
The use of β -blockers in T2DM has many benefits, yet familiar concerns such as 
hypoglycaemia masking brings about hesitance in using this therapy in this 
population. β -blockade is particularly useful in improving outcomes in T2DM patients 
with previous CVD.85 In the Diabetes Insulin-Glucose in Acute Myocardial Infarction 
(DIGAMI) study where diabetics post myocardial infarction were given β -blockers, 
there was a 50% reduction in mortality.86 In the cohort, one-hundred patients (17.6%) 
were receiving β-blockers. 
 
Females in the study had slighter higher blood pressures than the males, despite 
receiving more treatment. Women with T2DM have a significantly increased CVD risk 
compared with women without diabetes.87 In a US-based survey where heart 
disease related mortality had declined in non-diabetic women over time, the opposite 
was seen in diabetic women. 88 
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In this study, most patients were off target by the first 10 mmHg for both SBP and 
DBP. Perhaps given the cross-sectional limitations of this study and the short 
proximity by which targets are missed, patients are being managed in line with the 
prescribed national guidelines. This points out the challenges of treating patients to 
goal. Nonetheless, the hypertension treatment gap in T2DM has been well 
recognized and needs to be addressed far more aggressively in order to improve 
outcomes.89  
 
Glucose 
 
The management of hyperglycaemia is often considered the primary focus of 
diabetes care. Maintaining or improving glucose control may prevent or even delay 
the onset of microvascular complications in T2DM patients.6 There is also a modest 
reduction in macrovascular complications with tighter HbA1c. In the landmark UKPDS 
study, it was shown that for every 1% reduction in HbA1c, there is a 14% reduction in 
all cause-mortality, a 21% reduction in diabetes-related death, a 14% reduction in 
fatal and non-fatal MI, and a 16% reduction in the risk of heart failure.90 
 
There have been correlations between CVD and elevated postprandial glucose 
levels in patients with T2DM. 91 However, evidence from newer clinical trials does not 
support this contention.92 
 
The latest guidelines urge practitioners to treat patients to targets more difficult to 
reach and evidence suggests intensive HbA1c targeting is not the solution. Meta-
analysis 93 and randomized trials 46 demonstrated that overall mortality has not been 
impacted by massive reductions in HbA1c and treating to HbA1c of ≤ 6.5% has shown 
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no incremental benefit. In fact, the latest evidence suggests that further reductions in 
HbA1c increase the chance of hypoglycaemia which negatively impact patient 
outcomes. 94 It is no wonder that it has been proposed that HbA1c targets should be 
measured in terms of upper limits (e.g. 9%) as opposed to the current lower limits.95 
Glycated haemoglobin targets should remain 7%, but where appropriate, patients 
which require further reductions should have additional clinical attention given as 
they stand the added risk of hypoglycaemia, CVD or mortality. 
 
In the present study, HbA1c of ≤ 7% was achieved by over a quarter of the cohort, 
whilst the harder to reach IDF goal (HbA1c ≤ 6.5%) was reached by less. Just about 
as many which reached the HbA1c of ≤ 7% target were between the acceptable 7% - 
8% range. More than half had an HbA1c of >8%, which would require additional 
action to be taken as recommended by the ADA guidelines.48 
 
In the current study, 26.2% of patients reached HbA1c ≤ 7%. This result is poor in 
comparison to the 37.0%, 41.0% and 39.0% of patients achieving those same targets 
in studies conducted in Italy, Spain and the Czech Republic, respectively. 49 52 53 A 
separate Norwegian study showed that 35.0% of their patients where at goal for 
HbA1c ≤ 6.5%, almost double the amount of patients to be at goal for HbA1c in 
comparison to the current study (17.2%). 51 The South African 2006 had 
demonstrated a slightly better HbA1c of 30.7% in comparison to the current study. 
Results from the current study show that out of all the risk factors (blood pressure 
and serum lipids), HbA1c is being managed worse and in addition, far poorer 
compared to the other studies reviewed. Perhaps more attention is needed in order 
to achieve those desired HbA1c levels and as much as guidelines now recommend 
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more aggressive cardiovascular risk factor management, the treatment of HbA1c 
should not be left forgotten.  
 
Even though almost the entire cohort received glucose-lowering therapy, the failure 
to reach these targets remains disappointing. Patients on less intensive glucose 
lowering therapy (oral hypoglycaemics alone) had lower mean HbA1c levels than 
those receiving insulin alone. This may reflect the progressive nature of the diabetes 
mellitus condition or perhaps practitioners are substituting poor glucose control with 
more intensive treatment. 
 
In this study, patients with higher HbA1c levels tended to present with higher mean 
LDL-C levels. This may not necessarily signify that T2DM patients with raised HbA1c 
levels will have higher LDL-C levels. It may however point out that poor control of 
one risk factor is often accompanied by other poorly controlled risk factors.      
 
Biguanides (metformin) was used by 70% of patients as monotherapy or in 
combination with other treatment. Metformin, in the 850mg dosage form was the 
most commonly prescribed oral hypoglycaemic. There is evidence to suggest that 
metformin has vascular protective effects. In the UKPDS study, patients on 
combination metformin/sulphonylurea suffered more myocardial infarcts, strokes and 
cardiovascular mortality than those receiving metformin monotherapy. 96 In addition, 
metformin‟s weight neutral properties helped stabilize blood pressure levels in obese 
patients. Given the predisposition to cardiovascular disease and the frequent 
association of T2DM with obesity, metformin may in fact be the drug of first choice in 
these patients. 
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As previously mentioned, patients which present at this particular hospital are most 
often referral patients.  There were 454 (68.17%) patients receiving insulin as either 
mono or combination therapy. With so many insulin users comprising the cohort, it 
may be said that the study population was comprised of patients with an advanced 
stage of diabetes. On the other hand, perhaps practitioners are opting for insulin 
usage over oral hypoglycaemic therapy in an attempt to achieve better glycaemic 
control. Or perhaps insulin was favoured over oral hypoglycaemics as first line 
therapy? The missing data on diabetes duration as well as the cross-sectional nature 
of this study limits the understanding of this. Indeed, future studies should opt to 
include this parameter as it may shed some light on the greater use of insulin in 
T2DM patients.    
 
Lipids 
 
“From an initial perception that a disorder of glucose metabolism was the primary 
event in the pathogenesis of T2DM, there is now a growing appreciation that chronic 
elevation of free fatty acid (FFA) levels is an early event that contributes to the 
development of this disease. “ 97 
 
Despite having cholesterol levels similar to that of the general population, T2DM 
patients have lipid abnormalities which place them at high risk for cardiovascular 
disease and stroke. An epidemiological study demonstrated that T2DM patients have 
a 2 to 6 fold increased risk of cardiovascular disease and death. 98 T2DM 
management should routinely be considered secondary prevention, rather than 
primary prevention. The National Cholesterol Education Program (NCEP) recognizes 
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T2DM as “CVD-equivalent.” 99 Outcomes from the Framingham study set secondary 
prevention treatment for T2DM patients, similar to patients with a ≥20% risk of 
sustaining a cardiac event over the next ten years. Other patients classed into the 
same category as T2DM patients are those who have established CVD. 63 
 
Lipid management in T2DM patients remains poor. In a study conducted by Mehler 
et al, there was a consistent non-adherence trend to lipid guidelines for over 5 
years.100 In the current study, there were 275 patients (46.2%) with 
hypercholesterolaemia and 230 patients (39.8%) with hypertriglyceridaemia. Only 
half the cohort (53.85%) in the low risk category reached LDL-C SEMDSA targets 
(2.5 mmol/L) whilst much fewer (18.09%) reached targets in the high risk category 
(1.8 mmol/L). Patients not at goal for LDL-C were off by 0.81 mmol/L (2.5 mmol/L 
target) and 1.13 mmol/L (1.8 mmol/L target) on average. By lowering lipids in T2DM, 
vascular events and mortality can be drastically reduced. Clearly there needs to be 
an effective intervention in order to improve outcomes in T2DM patients. 
 
In comparison to the 53.8% of patients which reached the LDL-C target of 2.5 
mmol/L in the current study, 41.0% and 23.0% of patients achieved 2.6 mmol/L LDL-
C targets in two separate Spanish and Czech Republic studies, respectively.52 53  
Despite an easier target to reach, 16.5% and 32.0% of patients in separate Italian 
and Norwegian studies reached LDL-C of 3.0 mmol/L targets, respectively. 49 51 The 
results from the current study demonstrated that patients are achieving LDL-C 
targets far better than the other studies compared, including the previous 2006 study 
where 50.7% reached the LDL-C target of 2.5 mmol/L.55 Perhaps patients in the 
current study are being better managed for serum lipids through use of lipid-lowering 
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therapy or have a better knowledge of dietary modifications. One could argue that 
patients selected for the current study are being treated on a tertiary level, however, 
the Italian study had the poorest results, despite being conducted over 10 large 
hospital-based out-patient diabetes clinics. Outcomes from the Spanish study are 
most comparable to those obtained from the current study, both having similar LDL-C 
targets, similar level of patients achieving LDL-C targets and both study sites 
consisting of public referral hospitals. It is not clear why the last two last studies with 
targets of 3.0 mmol/L had such poor outcomes.   
 
Despite the wealth of evidence in favour of aggressive treatment of lipids in T2DM 
and treatment guideline recommendations, lipid-lowering therapy was only 
prescribed to just over half the cohort. The normal to slightly raised LDL cholesterol 
levels often makes lipid-lowering therapy unjustified for the primary prevention of 
cardiovascular disease in T2DM. However, clinical trials like CARDS 29 and others 28 
support the contention that lipid-lowering treatment in diabetic patients reduces CVD, 
regardless of baseline LDL-C levels.  
 
Patients in the current study were treated for both primary and secondary prevention 
on different levels; 317/563 patients (56.3%) and 78/103 patients (75.7%) were being 
treated for primary and secondary prevention, respectively. 
 
T2DM patients are at an increased risk of sustaining a cardiovascular event, 
especially those which should be treated for secondary prevention. Haffner et al. 
found that T2DM patients which previously had an MI, the risk of a recurrent event is 
nearly 50%.14 Poor guideline adherence and the lack of adequate therapy will lead to 
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costly surgical interventions and/or mortality if aggressive lipid-lowering treatment is 
not commenced. 
 
The high prevalence of CVD associated with T2DM is not unique to men, in fact, in 
the developed world it is the primary cause of death in females.101 In the present 
study, more females were being treated with statin lipid-lowering therapy (male 
56.9% vs. female 61.3%, not statistically significant, p = 0.449), yet had higher mean 
LDL-C levels (male 2.5 mmol/L (SD: 0.9) vs. female 2.7 mmol/L (SD: 0.9), not 
statistically significant, p = 0.052).  
 
T2DM patients tend to have small, dense and atherogenic LDL which may in fact be 
deceptive of the actual risk.45 Even if patients are achieving goal, statin therapy 
should be encouraged to lower the absolute risk of developing CVD.28 In the current 
study, patients (without previous CVD) receiving lipid-lowering therapy tended to 
have slightly higher mean LDL-C than those not receiving lipid-lowering therapy. With 
the disadvantages of cross-sectional studies, we can only assume that patients with 
higher LDL-C were only recently (just before the time of data collection) placed on 
lipid-lowering therapy and that levels were still to adjust. This reasoning can also be 
applied to where patients on lipid-lowering therapy tended to have higher prevalence 
of cardiovascular disease or stroke. The presence of cardiovascular history or a 
previous event may have encouraged the treating practitioner(s) to prescribe lipid-
lowering therapy for secondary treatment. Conceivably, due to the limited duration of 
therapy usage or poor patient compliance, those undeniable risk reductions offered 
by lipid-lowering therapy had yet to be realized. Perhaps the statin dosage was 
inappropriate and could have been adjusted. Simvastatin, particularly in the 
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20mg/day dosage was the most frequently prescribed. A comparison of target 
achievement by either receiving or not receiving lipid-lowering therapy favoured 
those on therapy to be more at goal.  
 
The use of statins in T2DM patients is beneficial. A study of 18 686 diabetic 
participants demonstrated that major vascular events (coronary events, stroke and 
coronary revascularisations) were reduced by a fifth for every mmol/L LDL-C reduced 
over 5 years. 102 With newer evidence available, there has been a progressive 
demand to lower LDL-C targets.103 Especially in high risk groups such as T2DM, 
lower LDL-C will lead to less cardiovascular disease and better patient outcomes. 
With newer and more potent agents available, future studies are needed to define 
what LDL-C levels are optimal and safe, as cholesterol forms a “core component in 
cellular membranes” of the body.104   
 
Until now, with the major impact statins have had on reducing CVD, their safety in 
the development of diabetes may have not been fully investigated. In a recent meta-
analysis, it was shown that with statin usage, there is a 9% increased risk in diabetes 
development. 105 The authors of the study recommended that statins be prescribed 
by doctors accordingly and that patients receiving statins should be screened for 
diabetes, particularly older patients. It was also mentioned that the slight risk of 
diabetes incidence is “favourably balanced by cardiovascular benefit.” Hence, 
although there is a slight risk of developing diabetes in patients using statins, the 
benefits of statins shouldn‟t be disregarded. Guidelines pertaining to statin use 
should still be followed, especially in those individuals that are high-risk of CVD.  
 
 
88 | P a g e  
 
Anti-platelet therapy 
 
The benefit of anti-platelet therapy in T2DM secondary prevention is well 
established.106 The prescribing of low-dose aspirin in the secondary treatment of 
CVD for T2DM is suggested in all the latest guidelines and has been “standard 
practice” for decades, not just in T2DM patients, but also for other high-risk 
populations. Despite T2DM patients having high risk for CVD, the use of aspirin for 
primary prevention remains controversial. T2DM patients with multiple risk factors 
should undoubtedly be treated for secondary prevention with aspirin anti-platelet 
therapy as they stand a far greater risk of sustaining coronary events. However, 
aspirin in primary prevention may not always outweigh its risks and the only evidence 
to suggest its use is based on “extrapolations from data from other high-risk 
populations.” 107 In a recent meta-analysis, the use of aspirin in diabetics for the 
primary prevention of major cardiovascular events showed no significant benefit.108 
The lack of conclusive beneficial evidence that this therapy has had in the primary 
prevention of diabetics warrants the need for more studies to be conducted. Two 
studies currently under way are: A Study of Cardiovascular Events in Diabetes 
(ASCEND ISRCTN60635500) and the Aspirin and Simvastatin Combination for 
Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D).109 In the present 
study, 40.7% and 54.4% of patients were being treated for primary and secondary 
prevention, respectively. Poor guideline adherence is clear, especially in those 
patients which should be treated with anti-platelet therapy for secondary prevention.  
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All Cardiovascular Risk Factors 
 
The use of aspirin and a statin in addition to targeted lowering of glucose and blood 
pressure is associated with reduction in cardiovascular risk in patients with T2DM. 
When these reductions are achieved all together, there may even be a greater 
benefit.43 Patients in the current study achieved LDL-C goals easier than blood 
pressure or glycaemic control (53.8% vs. 45.8% vs. 26.2% reached LDL-C, blood 
pressure and HbA1c targets, respectively). Less than 10% of the study population 
achieved the combined treatment goals for all three risk factors. The poor 
achievement of targets is in line with other studies. In an Italian study, where 2465 
patients were recruited, only 5% achieved the recommended goals for LDL-C, BP, 
glycated haemoglobin and smoking habits.49 Similarly, a Czech study concluded that 
1% of their patients achieved goals, whilst a Norwegian study consisting of 975 
patients had 6% of their total cohort at goal for the combined targets of glucose, BP 
and cholesterol control. 51 53 This may also demonstrate how challenging it is to 
control all risk factors in T2DM. 
 
Newer guidelines often set targets more difficult to achieve. However, the level of 
guideline adherence is often based on glycaemic control alone. The T2DM condition 
requires treatment which is multifactorial. It is no wonder so many patients are left 
undertreated. Lifestyle or dietary modification should also be stressed in addition to 
any pharmacotherapy. With the present challenges in treating T2DM patients, 
practitioners need to target all risk factors more aggressively. 
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Resources 
 
“The changing prevalence and incidence of DM is a major public health and 
economic problem.” 110 In 2002, the US economy spent $132 billion on diabetes. 111 
South Africa‟s resource limitations in the state sector are a constant reality. The 
number of doctors available to treat patients is limited. The selection of medications 
is subject to governmental formulary and may not always be the most effective 
available treatment. Short routine consultations, coupled with communication barriers 
lead to a major compromise in patient education. Improper lifestyle intervention, poor 
technique training leading to incorrect storage or administration of medicine such as 
insulin will surely result in poor diabetic control. The SEMDSA guidelines 
acknowledge patient education to be “cornerstone in effective diabetes care.” 56 In 
the DESMOND study, the benefit of a structured educational program for both new 
and previously diagnosed diabetics proved to have had a positive impact on weight 
loss and smoking cessation.112 It is pivotal for T2DM patients to be fully aware of 
their risk factors and know how to manage these effectively.113 Patients must also 
understand the chronic nature of the disease and their need to continue therapy for 
the rest of their lives. Better diabetes management is associated with better 
outcomes.114 As much as patient compliance is important, practitioner‟s convictions 
will also impact patient outcomes. 115 
 
On the positive, T2DM treatment gaps don‟t necessarily affect developing countries 
but also those with greater resources available. Despite the resource shortfalls of 
South Africa, the treatment gaps are in line with that of resource rich developed 
countries. Generally, further efforts in resource allocations and practitioner-patient 
communication are undoubtedly necessary to address disease management issues. 
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Limitations 
 
It could be said that data obtained from only one hospital may not entirely reflect the 
state of healthcare in the country. However, this study serves a very useful purpose 
and that is of, the value of auditing the level of care T2DM patients are receiving in a 
diabetes clinic at a major public sector academic hospital. Given the size and 
ethnicity ratios of the study cohort, the results may be a good representation of the 
South African population and may further be applicable to other major public 
hospitals across the country.  
 
The national SEMDSA guidelines are adapted from both US and European 
guidelines (ADA and ESC/EASD, respectively).  This may limit their application in the 
South African setting and may not be appropriate to benchmark the levels achieved 
(in the study) against international targets. With the South African population being a 
minority Caucasian, local future research will aid the development of guidelines that 
are better applicable to the South African population as whole. 
 
The current study was cross-sectional in design and may not have reflected the 
patients which prematurely passed away before the commencement of the study (i.e. 
those patients having the poorest control of risk factors). It was not an objective of 
the study, but future studies could be aimed at determining outcomes using 
longitudinal data.   
 
Data collected was done retrospectively. Due to the referral nature of the diabetic 
clinic, there were instances where patients had incomplete history. Some patients 
presented at the clinic whilst already controlled on therapy and did not require further 
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laboratory tests to be carried out. Some data may have been lost within the clinic. 
With details of weight, height, waist measurement, diet details and smoking status 
not found in the majority of patient files, calculations and classifications such as BMI 
and classification of the MS were omitted. Blood pressure readings were left out in 
some of the patient files and this is a large limitation to the study. Since hypertension 
and T2DM are components of the MS, it would have been worthwhile to determine 
the status of the cohort. Future studies should opt to include all necessary laboratory 
levels as well as other measurement parameters. 
 
There were also too few patients (5.86%) recruited in the Coloured population. It may 
be useful to recruit more Coloured patients in a future study.   
 
At the time of collection (July 2008-July 2009), practitioners may have used the 
previous SEMDSA 2003 guidelines to manage their patients. In this study, the latest 
SEMDSA 2009 guidelines were applied to the cohort. Despite this, practitioners, 
especially those working in an academic environment would have enough 
opportunities to revise or be updated (using circulations, meetings, seminars, 
literature etc) as to the latest treatment goals advised both nationally and locally.   
 
Conclusion 
 
“It has been shown that 85–95% of all diabetes cases are of type 2 in developed 
countries and this percentage is even higher in developing countries.” 3 
 
Aggressive targeting of HbA1c as well as blood pressure and dyslipidaemia is 
suggested by the latest T2DM treatment guidelines. 48 56 57 58 But are treatment 
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guidelines being adhered to in clinical practice and are treatment target goals being 
met? Certainly important, but even more so in developing countries such as South 
Africa where there less resources are available. 
 
Treating T2DM is challenging, it is no wonder that a large gap exists between 
practice and recommended treatment targets. Two previous studies conducted at the 
Charlotte Maxeke Johannesburg General Hospital demonstrated the under treatment 
of major cardiovascular risk factors in T2DM patients. 54 55 Using a larger sized 
cohort and the latest T2DM treatment guidelines, the current study was conducted to 
further evaluate the treatment gaps in T2DM. This study was not only conducted in 
order to augment our understanding of the treatment gap in the management of 
cardiovascular risk factors but indeed also to help influence modern day practice in 
the complexities of management in the T2DM condition. 
 
Numerous clinical trials have demonstrated the benefits of targeting and reducing 
blood pressure and lipid levels in T2DM.43 With so much focus centred around 
glucose control in the T2DM condition it is imperative that more attention is given to 
the above mentioned risk factors.  
 
There needs to be a more focused multi-factorial approach in managing the 
cardiovascular risk factors in these patients. Whether improvement lies in the form of 
therapeutic titration adjustment or an increase in patient education, there needs to be 
a more aggressive therapeutic approach to treating this high risk group of patients in 
order to reduce overall morbidity and mortality. 
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In conclusion, the study aimed to evaluate T2DM patients being treated in a 
resource-limited public sector setting hospital for CVD risk factors and to see whether 
they were being treated to goal. The majority of the cohort were treated with the 
necessary pharmacotherapy, but there still lies a gap in the reaching of treatment 
goals. Less than 10% of the cohort achieved the combined treatment goals for 
HbA1c, blood pressure and serum lipids. Indeed this indicates a poor level of goal 
attainment, however, in comparison to other studies; South Africa may have in fact 
achieved similar results with fewer resources available.  
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Case Report Form 
 
Figure 50 Case report form 
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Risk Factors For CVD Classified by Risk Group, Gender-Age Groups 
 
 
 
 
Risk Group Lower Risk - No CAD/Stroke Higher Risk - YES CAD/Stroke 
Age Group 
(years) 
≤ 55 55 - 65 ≥65 Overall ≤ 55 55 - 65 ≥65 Overall 
Gender 
Females (n = 322) Females (n = 47) 
n 101 118 103 322 8 14 25 47 
Total Cholesterol 
(mmol/L) 
4.64 4.73 4.67 4.68 5.35 4.45 4.86 4.83 
Triglycerides 
(mmol/L) 
1.72 1.73 1.61 1.69 2.21 1.63 1.96 1.92 
HDL-C  
(mmol/L) 
1.23 1.23 1.33 1.27 1.01 1.14 1.28 1.20 
LDL-C  
(mmol/L) 
2.59 2.70 2.60 2.63 3.33 2.47 2.70 2.75 
NAG COUNT (n) 40 53 47 140 8 10 23 41 
NAG Average 
LDL-C (mmol/L) 
3.42 3.22 3.25 3.29 3.33 2.66 2.82 2.88 
Mean Reduction 
needed (mmol/L) 
0.92 0.72 0.75 0.79 1.53 0.86 1.02 1.08 
% from Goal (%) 23.33 19.27 20.97 21.00 40.55 28.13 32.64 33.09 
         
Gender Males (n = 241) Males (n = 56) 
n 85 74 82 241 12 19 25 56 
Total Cholesterol 
(mmol/L) 4.53 4.38 4.11 4.34 4.75 5.09 4.29 4.67 
Triglycerides 
(mmol/L) 1.84 1.70 1.58 1.71 2.19 2.48 1.69 2.08 
HDL-C  
(mmol/L) 1.04 1.10 1.11 1.09 1.07 1.01 1.02 1.03 
LDL-C  
(mmol/L) 2.71 2.47 2.24 2.48 2.66 2.64 2.49 2.58 
NAG COUNT (n) 33 28 21 82 9 12 15 36 
NAG Average 
LDL-C (mmol/L) 3.49 3.34 3.14 3.35 3.19 3.03 2.85 2.99 
Mean Reduction 
needed (mmol/L) 0.99 0.84 0.64 0.85 1.39 1.23 1.05 1.19 
% from Goal (%) 25.12 21.67 19.40 22.48 39.85 37.56 32.72 36.12 
Table 9 Risk factors for CVD classified by risk group, gender and age group for study type 2 diabetic 
patients; Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), 
Coronary Artery Disease (CAD), Cardiovascular Disease (CVD), Not At Goal (NAG) 
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Exclusion of Participants in Type 2 Diabetes Study  
Figure 51 Exclusion of participants in type 2 diabetic study
Final Cohort
Exclusions
Initial Cohort 782 patients
673 Type 2 
Diabetics
672 Type 2 
Diabetics
671 Type 2 
Diabetics
666 Type 2 
Diabetics
666 Type 2 
Diabetics
5 Diabetics 
triglyceride > 
5mmol/L
1 Steroid 
Induced 
Diabetic
1 Gestational 
Diabetic
109 Type 1 
Diabetics
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The Use Of Statin Lipid-Lowering Therapy In Type 2 Diabetic Study Population 
  
Recieving Statin
Achieving LDL-C Goal 
Previous CAD/Stroke
LDL-Readings
Total Cohort n = 666
Yes
(n = 103)
Yes 
(n = 94) 
Yes
(n = 17)
Yes
(n = 9) 
No
(n = 8)
No 
(n = 77)
Yes
(n = 57)
No
(n = 20)
No 
(n =  9)
No
(n = 563)
Yes 
(n = 481) 
Yes
(n = 259)
Yes 
(n = 138) 
No
(n =121)
No
(n = 222)
Yes
(n = 108)
No
(n = 114)
No 
(n = 82)
Figure 52 The use of lipid-lowering therapy in type 2 diabetic study population; CAD/Stroke LDL-C target (1.8mmol/L) (left), No CAD/Stroke LDL-C target (2.5mmol/L) (right) 
1.8 mmol/L 2.5 mmol/L 
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Type 2 Diabetes Treatment Guidelines  
 
Treatment goal 
SEMDSA 
(2009) 
ADA 
(2008) 
IDF 
(2005 ) 
ESC/EASD 
(2007) 
Serum Glucose     
HbA1c (%) <7 <7 ≤6.5 ≤6.5 
Blood Pressure     
Systolic  (mmHg) <130 <130 <130 <130 
Diastolic (mmHg) <80 <80 <80 <80 
Systolic - Nephropathy patients 
(mmHg) 
≤120 ≤120 ≤120 ≤120 
Diastolic - Nephropathy patients 
(mmHg) 
≤70 ≤70 ≤70 ≤70 
Plasma Lipids     
Total Cholesterol  (mmol/L) <4.5 <4.5 <4.5 <4.5 
LDL-Cholesterol  (mmol/L) <2.5 <2.6 <2.5 <2.5 
LDL-Cholesterol - CAD/Stroke patients  
(mmol/L) 
≤1.8 ≤1.8 ≤1.8 ≤1.8 
HDL-Cholesterol - Male patients  
(mmol/L) 
>1.0 >1.0 >1.0 >1.0 
HDL-Cholesterol - Female patients 
(mmol/L) 
>1.2 >1.3 >1.2 >1.2 
Triglyceride  (mmol/L) <1.7 <1.7 <1.5 <1.7 
 
Table 10 Treatment goal summary for type 2 diabetics as set by different guidelines; Society for 
Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA), American Diabetes Association 
(ADA), International Diabetes Federation (IDF) and European Society of Cardiology / European Association 
for the Study of Diabetes (ESC/EASD), CAD/Stroke - In patients with established vascular disease such as 
ischaemic heart disease, cerebrovascular disease or peripheral vascular disease, LDL-C target: ≤ 1.8 
mmol/L 
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Criteria For The Diagnosis Of Type 2 Diabetes Mellitus - SEMDSA 
SEMDSA Guidelines for Diagnosis and Management of Type 2 
Diabetes Mellitus for Primary Health Care - 2009 
A.a Symptoms of diabetes plus 
 Casual/random plasma glucose >  11.1 mmol/lb                                       
Or 
 Fasting plasma glucose (FPG) >  7.0 mmol/lc                                       
 Or 
 2-h plasma glucose (2PG) > 11.1 mmol/l during OGTTd 
 
aThe classic symptoms of diabetes include polyuria, polydipsia and weight loss 
bCasual is defined as any time of day without regard to time of last meal 
cFasting is defined as no caloric intake for at least 8h 
dThe test should be performed as described by the World Health Organisation using 
a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in 
250ml water over 5 minutes 
Note: In the absence of unequivocal hyperglycaemia accompanied by acute 
metabolic decompensation a confirmatory laboratory glucose test (a FPG, a casual 
PG or a 2hPG in a 75-g OGTT) must be done in all cases on another day.  Different 
criteria are used to diagnose gestational diabetes in pregnant women. 
B. If  asymptomatic  
The 75g OGTT is indicated in the following:  
 In  the  asymptomatic high-risk individuals  
 If FPG is > 5.6 - <7.0 mmol/l (in detection / screening programmes ) 
 if random plasma glucose > 5.6 - <11.1† (on screening)  
† or do FPG. 
- WHO 1998 / 2006 criteria should be used to diagnose diabetes, including the 
importance of not diagnosing diabetes on the basis of a single laboratory 
measurement in the absence of symptoms. 
- Diagnosis should be based on laboratory plasma glucose (preferred) or capillary 
plasma glucose. 
- Conversion factor: plasma glucose (mmol/l) = 0.102 + 1.066 x capillary blood 
glucose. 
 
Table 11 Criteria for the diagnosis of type 2 diabetes mellitus; Society for Endocrinology, Metabolism 
and Diabetes of South Africa (SEMDSA) 
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Criteria For The Diagnosis Of Type 2 Diabetes Mellitus - ADA 
ADA Standards of Medical Care in Diabetes - 2008 
Criteria for the diagnosis of diabetes 
1. FPG 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at 
least 8 h.* 
OR 
2. Symptoms of hyperglycemia and a casual plasma glucose 200 mg/dl (11.1 
mmol/l). Casual is defined as any time of day without regard to time since last 
meal. The classic symptoms of hyperglycemia include polyuria, polydipsia, and 
unexplained weight loss. 
OR 
3. 2-h plasma glucose 200 mg/dl (11.1 mmol/l) during an OGTT. The test 
should be performed as described by the World Health Organization, using a 
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in 
water.* 
*In the absence of unequivocal hyperglycemia, these criteria should be confirmed by 
repeat testing on a different day. 
Criteria for testing for pre-diabetes and diabetes in asymptomatic adult 
individuals 
Testing should be considered in all adults who are overweight (BMI 25 kg/m2*) and 
have additional risk factors: 
 physical inactivity 
 first-degree relative with diabetes 
 members of a high-risk ethnic population (e.g., African American, Latino, 
Native 
American, Asian American, and Pacific Islander) 
  women who delivered a baby weighing 9 lb or were diagnosed with GDM 
 hypertension (140/90 mmHg or on therapy for hypertension) 
 HDL cholesterol level 35 mg/dl (0.90 mmol/l) and/or a triglyceride level 250 
mg/dl (2.82 mmol/l) 
  women with polycystic ovarian syndrome (PCOS) 
 IGT or IFG on previous testing 
 other clinical conditions associated with insulin resistance (e.g., severe obesity 
and acanthosis nigricans) 
 history of CVD 
2. In the absence of the above criteria, testing for pre-diabetes and diabetes should 
begin 
at age 45 years 
3. If results are normal, testing should be repeated at least at 3-year intervals, with 
consideration of more frequent testing depending on initial results and risk status.  
*At-risk BMI may be lower in some ethnic groups. 
 
Table 12 Criteria for the diagnosis of type 2 diabetes mellitus; American Diabetes Association (ADA) 
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Criteria For The Diagnosis Of Type 2 Diabetes Mellitus - IDF 
International Diabetes Federation – Global Guideline For Type 2 
Diabetes 
Screening and diagnosis 
 
Each health service should decide whether to have a programme to detect people 
with undiagnosed diabetes. 
 
 This decision should be based on the prevalence of undiagnosed diabetes 
and on the resources available to conduct the detection programme and 
treat those who are detected. 
 
 Universal screening for undiagnosed diabetes is not recommended. 
 
 Detection programmes should target high-risk people identifi ed by 
assessment of risk factors. 
 
Detection programmes should use measurement of plasma glucose, preferably 
fasting. 
 
For diagnosis, an oral glucose tolerance test (OGTT) should be performed in people 
with a fasting plasma glucose ≥5.6 mmol/l (≥100 mg/dl) and <7.0 mmol/l (<126 
mg/dl). 
 
Where a random plasma glucose level ≥5.6 mmol/l (≥100 mg/dl) and <11.1 mmol/l 
(<200 mg/dl) is detected on opportunistic screening, it should be repeated fasting, or 
an OGTT performed. 
 
The WHO 1999 criteria (1) should be used to diagnose diabetes; these include the 
importance of not diagnosing diabetes on the basis of a single laboratory 
measurement in the absence of symptoms. 
 
People with screen-detected diabetes should be offered treatment and care. This 
guideline does not deal with lesser degrees of hyperglycaemia detected on 
screening. 
 
This guideline does not deal with lesser degrees of hyperglycaemia detected on 
screening. 
 
World Health Organization. Definition, Diagnosis and Classification of Diabetes 
Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and 
Classification of Diabetes Mellitus. Geneva: WHO Department of Non-communicable 
Disease Surveillance. 1999: 1-59. http://www.who.int 
 
 
Table 13 Criteria for the diagnosis of type 2 diabetes mellitus; International Diabetes Federation 
(IDF) 
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 Criteria For The Diagnosis Of Type 2 Diabetes Mellitus – ESC/EASD 
European Society of Cardiology / European Association for the Study  
of Diabetes (ESC/EASD) 
Impaired glucose tolerance (IGT) can be recognized by the results of OGTT only: 2-h 
post-load plasma glucose (2hPG) 7.8 and 11.1 mmol/L (140 and 200 mg/dL). 
 
A standardized OGTT test performed in the morning, after an overnight fast (8–14 h); 
one blood sample should be taken before and one 120 min after intake of 75 g glucose 
dissolved in 250–300mL water in a course of 5 min (note: timing of the test is from the 
beginning of the drink). 
 
The currently valid clinical classification criteria have been issued by WHO and ADA. 
These are currently under review by WHO and updated criteria will be introduced soon. 
The WHO recommendations for glucometabolic classification are based on measuring 
both fasting and 2-hPG concentrations and recommend that a standardized 75 g OGTT 
should be performed in the absence of overt hyperglycaemia. 
 
 
 
WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World 
Health Organisation; 1999. Report no. 99.2. 
 
 
Table 14 Criteria for the diagnosis of type 2 diabetes mellitus; European Society of Cardiology / 
European Association for the Study of Diabetes (ESC/EASD) 
